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Abstract
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the
United States in people who are 50 and older. The safety and efficacy of aflibercept for
the treatment of late stage neovascular AMD (NAMD) has been demonstrated by clinical
trials among several populations; however, it is unclear whether all NAMD patients
respond in the same manner as was studied in the clinical trials. The purpose of this
study was to examine if populations of patients treated with aflibercept for the treatment
of NAMD were significantly different from one another in terms of health characteristics,
treatment regimens, and treatment outcomes. The burden of treatment theory was used to
guide this study. Data collected from electronic medical records were used to investigate
NAMD characteristics 199 patients from 3 private, retinal practices in the United States.
Data were analyzed using one-way ANOVA, c2, Spearman’s correlation, and pointbiserial correlation tests. The results of this study showed the specific retinal practice
populations of NAMD patients treated with aflibercept were generally similar with
respect to selected health characteristics, treatment regimens, and treatment outcomes.
By using the information reported from this research, public health initiatives can be
developed that focus on the need for early detection of AMD to capture changes that
represent NAMD and move to early treatment for better outcomes. The positive social
change that could result from this research is that retinal specialists may gain insight into
the use and outcomes of aflibercept treatment.
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Chapter 1: Introduction to the Study
Introduction
Age-related macular degeneration (AMD) is the leading causes of blindness in the
United States in people 50 years of age and older (National Eye Institute [NEI], 2014).
Further, the NEI (2014) reported the U.S. 2010 prevalence of AMD for all ages and all
races/ethnicities to be 2.09% translating to 2,069,403 cases. Projections for increase in
AMD are estimated to be 3,664,044 by 2030 and 5,442,265 by 2050 (NEI, 2014). The
majority of patients with AMD of all types are Caucasian (prevalence 2.46%) and 86% of
patients with AMD are female (NEI, 2014). The risk of developing AMD increases
significantly with aging from 0.36% in the 50s to 11.73% in the 80s (NEI, 2014).
The burden of AMD encompasses not only vision loss, but also issues of
depression, falls, and cost in time and finances for treatment (Dawson, Mallen,
Gouldstone, Yarham, & Mansell, 2014; Silver, 2014; Wood et al., 2011). Treatment for
neovascular AMD (NAMD) with current vascular endothelial growth factor inhibitors
(anti-VEGF) was estimated to be approximately 1 to 2 billion dollars per year, which is
approximately 10% of the total Medicare Part B drug apportionment budget per year
(Silver, 2014). One objective of the U.S. health improvement and disease prevention
program, Healthy People 2020, is to reduce the incidence of AMD by 10% from 15.5 per
1,000 individuals to 14.0 per 1,000 (Department of Health and Human Services [DHHS],
2015). More specifically, the goal is to reduce the impact of visual impairment and
disability caused by AMD in the population in which AMD is most prevalent (i.e.,
individuals 45 years of age and older; DHHS, 2015). In support of this objective,
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researchers in ophthalmology investigate disease mechanisms and risk factors in order to
design and develop novel therapeutic interventions in this disease population (Avery et
al., 2014; Hagstrom et al., 2013; Kovach, Schwartz, Flynn, & Scott, 2012).
Before being marketed, therapeutic interventions must undergo strict clinical
research testing according to the U.S. Food, Drug, and Cosmetic Act (Federal Food,
Drug, and Cosmetic Act, 1938). While clinical trials are performed to establish the safety
and efficacy of new therapies, research at this level can only begin to describe how a
therapeutic agent may perform in all populations in which the disease manifests (Drolet
& Lorenzi, 2011). Consequently, researchers must continue to evaluate interventions in
targeted populations to provide ongoing information pertinent to the use of new therapies.
Elucidating information, such as ongoing evaluation of therapeutic agents, could lead to
positive social change by ensuring developers of new drug products take into
consideration how differences in population characteristics could impact clinical
outcomes.
In Chapter 1, I will examine the background of AMD and provide information
pertaining to how this study extended the knowledge base regarding use of aflibercept in
NAMD by evaluating selected health characteristics, treatment regimens, and treatment
outcomes of a novel therapeutic intervention in populations of NAMD patients. In
Chapter 1, I will also elaborate the nature of the study performed, including the research
questions and hypotheses addressed in the study. In the remainder of Chapter 1, I will
address the assumptions, limitations, and significance of this research, and I will preview
the remaining chapters.

3
Background of the Study
AMD is a progressive and chronic ophthalmic condition wherein changes to the
macula of the eye manifest and have an impact on visual function (Lim, Mitchell,
Seddon, Holz, & Wong, 2012). The various phases of AMD are characterized by
increasingly severe anatomical manifestations ranging from (a) early AMD wherein fatty
deposits (i.e., drusen) form that create little visual disturbance (NEI, 2015b); (b)
intermediate AMD, in which drusen become larger and changes in the color and
appearance of the retinal pigment epithelium (RPE) become evident (NEI, 2015b); and
(c) the late phase, in which either increased atrophy in the RPE, choriocapillaris, and
photoreceptors, known as geographic atrophy (GA), or the development of new blood
vessels into the choroidal space of the macula, known as choroidal neovascularization
(CNV), manifests (Lim et al., 2012). Risk factors noted to be associated with AMD,
include increased age, cigarette smoking, cataract extraction, and family history of AMD
(Chakravarthy et al., 2010). Lim et al. (2012) further noted hyperopic refraction and
sunlight exposure as significant risk factors.
The early and intermediate forms of AMD have little impact on visual function;
therefore, prophylaxis rather than treatment is the focus of these phases (Singer, Amir,
Herro, Porbandarwalla, & Pollard, 2012). Once a patient’s disease has progressed to
NAMD, the standard of care treatment is injections with anti-VEGF drugs (e.g.,
ranibizumab, bevacizumab, or aflibercept) that are designed to inhibit proliferation of
new blood vessels (Gower, 2012; Rakic et al., 2013). In general, anti-VEGF injections
are intended to be given on a monthly basis for at least 3 months after which the schedule
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of additional injections is based on visual function results achieved (Kovach et al., 2012;
Rakic et al., 2013). Obviously, treatment outcomes vary; however, investigators have
reported that patients may regain as much as 50% of the vision lost in the initial
onslaught of NAMD, if the condition is caught early (Lim et al., 2012). The three antiVEGF drugs currently approved for treatment of NAMD (i.e., Avastin, Macugen, and
Eylea) are quite costly and make up a substantial portion of Medicare Part B payouts
(Levinson, 2011). A fourth drug, bevacizumab, is often used “off label” to treat NAMD
as it is significantly cheaper than the alternatives; however, the practice of “off label”
treatment with bevacizumab has not been supported by the Office of Inspector General as
its safety and efficacy have not been evaluated in the NAMD population (Levinson,
2011).
Through the process of deduction, I determined an appropriate approach for this
study to be to evaluate the gap in the discipline that existed regarding specifically
identified populations to determine whether selected health characteristics, treatment
regimens, and treatment outcomes were significantly different between population
centers. Furthermore, I determined the need to evaluate what associations existed
between selected health characteristics, treatment regimens, and treatment outcomes in
the selected population centers. The results of a study exploring the identified gap should
lead to a better understanding of not only which patients should be treated and what the
best treatment regimen was for the optimal outcome but also what impact treatment had
on personal and public heath burden.
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Problem Statement
While the safety and efficacy of aflibercept for the treatment of NAMD was
demonstrated in clinical trial populations to the satisfaction of the Food and Drug
Administration (FDA; Heier et al., 2012), the issue of ongoing evaluation of this
treatment continues. As with prior anti-VEGF treatments, the matter was unclear
whether all populations of NAMD respond in the same manner as was studied in the
clinical trials used to support the marketing of aflibercept (Al-Qureshi & Shaikh, 2012;
Chakravarthy et al., 2012; Rakic et al., 2013). NAMD treatment costs make up a
substantial portion of the payouts made by Medicare; therefore, appropriate treatment of
patients who will gain the most benefit is of utmost importance to both the personal and
public financial burden created by NAMD (Schmier, Covert, & Lau, 2012; Silver, 2014;
Stein, Hanrahan, Comer, & Sloan, 2013).
By evaluating selected health characteristics, aflibercept treatment regimens, and
aflibercept treatment outcomes of NAMD patients in geographically disperse population
centers, I aimed to add to the body of knowledge pertaining to how aflibercept was being
used, should be used, and in what patient populations aflibercept was the most
appropriate treatment. My goal was to address whether significant differences existed
regarding selected health characteristics, treatment regimens, and treatment outcomes for
patients with NAMD treated with aflibercept from three private, retinal practices in
geographically disperse population centers in the United States. Potential associations
between selected health characteristics, treatment regimens, and treatment outcomes were
evaluated to address the gap in the literature related to aflibercept and how aflibercept
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treatment for NAMD performs in populations with characteristics different from or
treated in a manner that differed from the clinical trial populations.
Purpose of the Study
The primary purpose of this quantitative, secondary data analysis was to
determine if differences exist between geographically disperse NAMD patient
populations treated with aflibercept (grouping variable) with regard to selected health
characteristics (independent variables). The secondary purpose was to evaluate
associations that may be present between populations. This evaluation would aid in
determining if and how selected health characteristics (independent variables) and
aflibercept treatment regimens (independent variables) impacted treatment outcomes
(dependent variables).
Research Questions and Hypotheses
I conducted evaluations using patients from three private, retinal practices in
geographically disperse populations centers in the United States who had been diagnosed
with NAMD and had been treated with aflibercept. The following research questions
were addressed:
Research Question 1: Were there significant differences between selected health
characteristics of populations of NAMD patients treated with aflibercept in three
private, retinal practices in geographically disperse population centers in the
United States? Health characteristic variables included: age, gender, number of
ocular comorbidities, number of systemic comorbidities, number of days between
NAMD diagnosis and first treatment with aflibercept in the study eye, baseline
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best corrected visual acuity (BCVA), and baseline optical coherence tomography
(OCT).
H01: µ1=µ2
There were no differences in proportions between selected health
characteristics of populations of NAMD patients treated with aflibercept
in three private, retinal practices in geographically disperse population
centers in the United States.
Ha1: µ1≠µ2
There were differences in proportions between selected health
characteristics of populations of NAMD patients treated with aflibercept
in three private, retinal practices in geographically disperse population
centers in the United States.
Research Question 2: Were there significant differences between aflibercept
treatment regimens used to treat NAMD patient in three private, retinal practices
in geographically disperse population centers in the United States? Treatment
regimen variables included: average number of aflibercept treatments injections
received during 1 year from initial aflibercept treatment and average number of
days between aflibercept treatments.
H02: µ1=µ2
There were no differences in the aflibercept treatment regimens used to
treat populations of NAMD among patients at three private, retinal
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practices in geographically disperse population centers in the United
States.
Ha2: µ1≠µ2
There were differences in aflibercept treatment regimens used to treat
populations of NAMD among patients at three private, retinal practices in
geographically disperse population centers in the United States.
Research Question 3: Were there significant differences between aflibercept
treatment outcomes reported for NAMD patients in the three private, retinal
practices in geographically disperse population centers in the United States?
Treatment outcome variables included: average change from baseline in BCVA
and average change from baseline in OCT.
H03: µ1=µ2
There were no differences between aflibercept treatment outcomes
reported for NAMD patients in three private, retinal practices in
geographically disperse population centers in the United States.
Ha3: µ1≠µ2
There were differences between aflibercept treatment outcomes reported
for NAMD patients in three private, retinal practices in geographically
disperse population centers in the United States.
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Research Question 4: What associations existed between selected health
characteristics and aflibercept treatment regimens used to treat NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H04: ßĸ=0
There were no associations between selected health characteristics and
aflibercept treatment regimens used to treat NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Ha4: ßĸ≠0
There were associations between selected health characteristics and
aflibercept treatment regimens used to treat NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Research Question 5: What associations existed between selected health
characteristics and aflibercept treatment outcomes reported for NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H05: ßĸ=0
There were no associations between selected health characteristics and
aflibercept treatment outcomes reported for NAMD patients in three
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private, retinal practices in geographically disperse population centers in
the United States.
Ha5: ßĸ≠0
There were associations between selected health characteristics and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Research Question 6: What association existed between aflibercept treatment
regimens used and aflibercept treatment outcomes reported for NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H06: ßĸ=0
There were no associations between aflibercept treatment regimens used
and aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Ha6: ßĸ≠0
There were associations between aflibercept treatment regimens used and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
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Theoretical Framework
May, Montori, and Mair (2009) described the theoretical framework of burden of
treatment as based on recognition that chronic disease was increasingly burdensome for
patients, not just because of the health issues related to the disease, but also due to the
treatments prescribed for chronic diseases. May et al. discussed the impact complicated
treatments may have on patients due to nonadherence as causing additional health
complications along with financial and health burdens associated with changes in health
status. These researchers called for minimally disruptive treatments and treatment
regimens that could be managed by patients with chronic conditions. May et al. (2014)
further elaborated on the burden of treatment theory as being the predominant manner by
which to describe a patient’s “struggles to endure the symptoms of illness and to look
after themselves and others” (p. 1).
As the life span of humans has increased, the face of illness has changed from
acute, infectious disease to chronic, long-term, debilitating conditions that pose not only a
burden based on the need to endure the symptoms but also based on the ongoing need to
address treatment of the condition (May et al., 2014). The treatment paradigm expands
further when one chronic, long-term disease leads to additional comorbidities that each
have specialized healthcare providers, treatments, and treatment schedules and results in
conditions that are no longer cured, as in the case of infections, but rather must be
managed for the remainder of the patient’s life span (May et al., 2014). Previously,
illness and its cure were predominantly a burden under the purview of the healthcare
provider (May et al., 2014). With the change to long-term management, the burden of
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illness and treatment have been shifted by healthcare providers to the patient, who is
accountable for managing time, treatments, compliance, and self-care along with the
other activities of normal life (May et al., 2014). In order to be managed, the burden
must be distributed within a patient’s network of friends, family, and caregivers. These
issues, then, become the burden not just of the illness but also of the treatment for the
illness (May et al., 2014).
NAMD meets the criteria of being a long-term, debilitating disease that requires
management by a specialized healthcare provider; specialized treatments that forestall or
prevent progression; and the use of a patient’s network of friends, family, and caregivers
in order to manage not just the burden of illness (e.g., assistance with activities of daily
living for prevention of comorbidities that impact quality of life [QOL]) but also the
burden of treatment (e.g., multiple visits to physicians to receive complicated treatments)
(May et al., 2014). By evaluating specific populations of NAMD patients treated with
aflibercept, my purpose for this study was to assess whether selected health
characteristics, treatment regimens used, and treatment outcomes differed from what had
been noted in prior literature. Further, I evaluated the presence or absence of associations
between health outcomes, treatment regimens, and treatment outcomes as a secondary
analysis to determine if the burden of treatment was being assigned to appropriate
populations.
Nature of the Study
This study was a retrospective, contrasted group, cross-sectional, secondary
analysis of data obtained from three geographically disperse NAMD patient populations
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wherein the patients had been treated with aflibercept. I evaluated specific selected
health characteristics, treatment regimens, and treatment outcomes across the three
populations to determine whether differences and associations existed. Advantages of
using secondary data analysis were that the study was relatively economical and made
use of data that was available but had not been previously analyzed in the manner
proposed (Green & Salkind, 2010). Disadvantages of the secondary analysis design
included that the fit of the data available for the questions explored were not always
appropriate, and the quality of the data was not as accurate as data collected as primary
data (Green & Salkind, 2010). These data were analyzed by ANOVA, Welch ANOVA,
c2 analysis, point-biserial analysis, or Spearman’s rank-order correlation of the various
selected health characteristics, treatment regimens, and treatment outcomes.
Definitions
Age-related macular degeneration (AMD): Progressive and chronic ophthalmic
condition wherein changes to the macula of the eye manifest and have an impact on
visual function (NEI, 2015b)
Early Treatment Diabetic Retinopathy Study (ETDRS) charts: Visual acuity
testing charts utilized in clinical trial applications (Kaiser, 2009)
Neovascular AMD (NAMD): The later stage of AMD in which new, leaky blood
vessels grow into the macular region of the eye and cause catastrophic changes in the
macular tissues resulting in central visual changes that may become permanent blindness
if not treated (NEI, 2015b)
Logarithm of the mean angle of resolution (logMAR): the notation that is used to
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indicate the visual acuity achieved when using ETDRS charts (Kaiser, 2009)
Macula: A small area near the center of the retina, the health of which is
necessary for maintaining sharp, central vision that allows individuals to see directly
ahead (NEI, 2015b)
Oculus Dexter (OD): Right eye (“Oculus dexter,” 2009)
Oculus Sinister (OS): Left eye (“Oculus sinister,” 2009)
Oculus Uterque (OU): Both eyes (“Oculus uterque,” 2009)
Optical Coherence Tomography (OCT): An imaging technique that uses light to
provide cross-sectional images of tissues (Fujimoto, Pitris, Boppart, & Brezinski, 2000).
It is used in ophthalmic indications to visualize the retinal tissue.
Visual Acuity (VA): The measure of the clarity of an individual’s vision. This
measurement specifically deals with the ability of the visual system to resolve spatial
details (Committee on Disability Determination for Individuals with Visual Impairments,
National Research Council, Division of Behavioral and Social Sciences and Education, &
Board on Behavioral, Cognitive, and Sensory Sciences, 2002)
Assumptions
My primary assumption for this study was that the data to be gathered at the
various geographic locations were assumed to be characteristic of the general population
of patients being treated with aflibercept; therefore, these data could be used to describe
what the general population characteristics were, what treatment regimens were being
used, and what treatment outcomes were experienced in these populations. I also
assumed that all patients who had NAMD in these retinal practices had been
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appropriately coded per International Classification of Disease, Version 9 (ICD-9) of
362.52 (exudative senile macular degeneration of retina). Finally, I assumed that those
patients with the ICD-9 code of 362.52, after the approval of aflibercept in 2011, were
given the opportunity to be treated with aflibercept.
Scope and Delimitations
I carried out this study in a specific subpopulation of the AMD general
population, NAMD. The rationale for culling the NAMD subgroup from within the
larger AMD general population was that more treatment options were available in the
selected population than in the non-NAMD populations (National Institutes of Health
[NIH], 2014). Also, the NAMD population was more easily identified as patients were
actively seeking treatment from medical professionals due to noticeable loss of vision
(Singer et al., 2012). While it was important to understand the characteristics of NAMD
populations and the reality of how patients were identified and treated for NAMD,
evaluating NAMD populations may advance the larger question of generalizability and
applicability of clinical research versus general patient populations in other therapeutic
areas.
Limitations
General NAMD population characteristics may be able to be identified easily
through public databases; however, treatments and treatment outcomes are not typically
provided in public databases. As such, it was necessary to identify and gain the consent
of retina specialists in various parts of the country to capture information to evaluate
demographic and selected health characteristics as well as treatment regimens and
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treatment outcomes for NAMD patients treated with aflibercept. Gaining access to
electronic medical records (EMR) data that were consistent across the three retinal
centers limited what could be analyzed in this study. Consistency in data capture
between retinal centers was a key element to the design of the study as this was the
method of establishing the populations as single entities and as a collective. Without
consistency, my ability to determine the impact of the independent variables on the
dependent variable was limited. To avoid issues of consistency, I evaluated EMR
systems at retinal practices to determine whether all the proposed variables were present
and what format was used to capture findings. A final limitation was that the potential
associations between selected health characteristics, treatment regimens, and treatment
outcomes may have been subtle enough so as not to be detected in this study.
Significance of the Study
By using secondary analysis of EMR data in a variety of NAMD populations
treated with aflibercept, I was able to perform evaluations to assist in understanding
population differences. Researchers have speculated about different populations of
NAMD and what the outcome of treatment with anti-VEGF medications might be (Heier,
2013). The results of this study could add to the body of knowledge pertaining to how
aflibercept was being used in retinal practices treating NAMD patients and elucidate the
impact differences in population outcomes have on personal and public health. Since
NAMD treatment makes up a significant portion of the public financial burden in the
form of Medicare payouts, determining if patients being treated were those that received
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the greatest benefit from treatment was an important question to answer (Schmier et al.,
2012; Silver, 2014; Stein et al., 2013).
Significance to Practice
Significant differences in health characteristics, treatment regimens, and treatment
outcomes that could be observed between the NAMD populations would aid in defining
the importance this has on public health and clinical research. If this findings of this
study were to show that there were differences existed between the populations
identified, research into the development of different types of sampling methods, research
study designs, or methods of translation from clinical research to clinical practice would
be beneficial (Kessler & Glasgow, 2011; Lenfant, 2003; Sung et al., 2003). The social
benefit of creating better testing methods could result in moving clinical research in a
direction that is more beneficial to a greater portion of the disease population, thereby
creating better outcomes and stronger evidence-based information on which the public
can rely (Kessler & Glasgow, 2011; Lenfant, 2003). Creating more interest in clinical
research could also increase confidence that the process of clinical research, as a valuable
part of product development and translation of study findings from clinical research to
clinical practice, would be more valuable (Drolet & Lorenzi, 2011; Kessler & Glasgow,
2011; Lenfant, 2003).
Significance to Social Change
The positive social change implication of this study was to gain a better
understanding of how treatment outcomes were affected by selected health characteristics
and treatment regimens in NAMD. Having a better understanding could lead to more
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appropriate information about treatment options for AMD and NAMD patients and could
inform the design of AMD and NAMD clinical studies to represent more accurately the
target population in which the therapeutic intervention was to be used. Further, public
health initiatives could be designed to identify at-risk AMD and NAMD populations to
provide education germane to the need for early diagnosis and treatment. The impact on
the personal, familial, and societal burdens related to blindness could be ameliorated by
use of summary information provided to public health organizations, medical
professionals, and patients.
Summary
NAMD is a significant a public health issue since it has a substantial economic
and health impact both at the individual and population levels. The aim of this study was
to assess selected health characteristics, treatment regimens, and treatment outcomes in
NAMD patients treated with aflibercept in geographically disperse retinal practices in the
United States to determine whether there were differences in the populations, and
secondarily, to evaluate what associations existed between the selected variables.
Ascertaining whether differences existed between populations of NAMD patients was
clearly of importance in making the appropriate translation of findings from the clinical
trial phase into the clinical treatment phase. Treating appropriate patients with
appropriate interventions could lessen the burden of illness on both patient and the public.
In Chapter 1, I provided a general overview of the study, including the background of the
study, the problem statement, the purpose of the study and the associated research
questions and hypotheses. The theoretical framework of burden of treatment theory was
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introduced along with how this theory related to the research problem. Furthermore, I
reviewed the nature of the study, definitions, assumptions, scope and delimitations,
limitations, and significance of the study. In Chapter 2, I will review research relevant to
NAMD; general population characteristics, including risk factors, comorbidities, and
genetic profiles; and current therapeutic intervention with anti-VEGF treatments.
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Chapter 2: Literature Review
Introduction
Aflibercept treatment for NAMD has been clinically tested and approved by the
FDA (2011); however, the selected health characteristics, treatment regimens, and
treatment outcomes experienced by general patient populations may or may not differ
from each other and the way the clinical research studies were conducted. In this study, I
evaluated three geographically disperse population centers to determine whether there
were differences between NAMD patients treated with aflibercept, and secondarily,
whether associations existed between selected health characteristics, treatment regimens,
and treatment outcomes. In this chapter, a description of the methods I used to identify
appropriate literature for this chapter will follow the introduction. Moreover, I will
provide a review of literature identified to support the theoretical framework of burden of
treatment. The following section will be a description of the risk factors associated with
NAMD, the prevalent types of treatment for NAMD, and associated treatment outcomes.
Additionally, I will present the evaluation of interventions used to treat NAMD including
treatment regimens, especially as compared to those used in clinical trials. I will also
discuss treatment outcomes to elucidate the need to determine how selected health
characteristics and treatment regimens may impact outcomes. Finally, a summary of the
literature review will conclude the chapter.
Literature Search Strategy
This literature review was based on my search for relevant literature using Google
and Google Scholar search engines as well as direct literature searches using Walden
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University Library’s Thoreau search of all applicable databases. The search was focused
on peer-reviewed, full text articles that were published between the years 2011 through
2015. In some cases, it was necessary for me to purchase a full text article when I
determined that the information the article contained would significantly contribute to the
literature review. Websites for the following associations or agencies were also used in
the literature search: Age-Related Eye Disease Study (AREDS), American Academy of
Ophthalmology, Association for Research in Vision and Ophthalmology, American
Foundation for the Blind, U.S. Census Bureau, U.S. Centers for Disease Control and
Prevention, FDA, National Center for Advancing Translational Science, NEI, and NIH.
Keywords used alone or in combination included: age-related eye disease study, agerelated macular degeneration, AMD, anti-VEGF, AREDS, behavior, burden,
comorbidities, diet, environment, ethics, ethnicity, genetics, neovascular, race, risk
factor, side effect, translation, treatment, and vascular endothelial growth factor. These
searches yielded a wide range of articles that proved to be applicable to this study for
burden of treatment, AMD, NAMD, treatments, and treatment outcomes. Since the
burden of treatment theory was a relatively new concept, fewer articles that pertained to
this subject were available. I used a total of nine articles that either discussed the burden
of treatment or evaluated burden of treatment in a chronic condition or began the
discussion of developing an instrument to measure the burden of treatment in patient
populations. I located approximately 43 appropriate aflibercept treatment covering issues
including initial results of clinical trials in treatment-naïve subjects, use of aflibercept
after treatment with other anti-VEGF treatments, use of aflibercept in polyploidal
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choroidal neovascular AMD, and use of aflibercept in treatment resistant patients.
Approximately 480 articles were identified that pertained to some aspect of AMD,
including phases, risks, burden of disease, epidemiology, treatments, and outcomes. I
used this information to build a literature-based framework for the study investigating
different population centers to determine whether there were differences in the selected
health characteristics, aflibercept treatment regimens, and aflibercept treatment outcomes.
Theoretical Framework
The burden of treatment theory aims to facilitate a new understanding of the
interaction between capacity for action and the work that healthcare systems pass on to a
patient and his or her relational networks” (May et al., 2014, p. 2). May, Montori et al.
(2009) began the discussion of burden of treatment due to the increasing disease burden
experienced by patients with chronic diseases, which have displaced acute, infectious
diseases as the main cause of ill health. Tran et al. (2012) noted that around 45% of the
general population currently live with at least one chronic disease. This increases to
approximately 88% as individuals reach 65 or older (Tran et al., 2012). May, Montori et
al. also explained that the burden of disease theory was not only about the disease.
Bearing the burden of a disease also means bearing the burden of its treatments (May,
Montori et al., 2009). A patient is no longer a bundle of symptoms to be cured by acute
treatment, but rather patients must engage in a multitude of treatment and service
interactions that require management (May, Montori et al., 2009). This situation is
aggravated as patients acquire multiple comorbidities having competing treatments,
services, outcomes, and impact on each other (May, Montori, et al., 2009). The
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imperative of the theory was to identify and address issues “to help alleviate treatment
burden and tailor treatment regimens to the realities of people’s daily lives” (Sav et al.,
2013, p. 312).
May et al. (2014) described the process by which burden of treatment theory was
derived. The initial focus of the researchers was on normalization process theory in
which the ways an individual incorporates new ideas, methods, or ways of thinking or
working into the fabric of his or her life (May, Mair et al., 2009). Normalization process
theory was also the foundation of minimally disruptive medicine as described in May,
Montori et al. (2009). As normalization theory applies to chronic disease, May et al.
(2014) explained that chronic disease treatment management must become embedded
into a patient’s normal daily activities for the patient to manage the lifetime trajectory of
his or her illness. Previously, the management of treatment and services related to illness
were the purview of the physician and his or her staff (May et al., 2014). The work of
managing chronic disease has now been transferred to the patient, who may have little
understanding of the complexities of managing single chronic illness issues let alone
those associated with multiple multimorbid conditions (May et al., 2014).
The cumulative complexity model, as elaborated by Shippee, Shah, May, Mair,
and Montori (2012), supported the issue of the complexity faced by patients with chronic
multiple multimorbid conditions and was the second conceptual model that was
formative in the development of burden of treatment theory. The cumulative complexity
model deals specifically with how the work of managing healthcare has been transferred
to patients and how this management was best structured to facilitate his or her meeting
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the demands of additional healthcare work (Shippee et al., 2012). Indeed, as the need for
treatment in multiple multimorbid conditions accumulates, the work that must be
managed to accomplish all that is necessary with regard to treatment, self-monitoring,
attention, and coordination can become overwhelming to a patient resulting in confusion,
nonadherence, poor health outcomes, and inappropriate resource utilization (May et al.,
2014). Finally, May et al. (2014) described concepts pertaining to “demand, self-care,
and social networks” (p. 282) as espoused by Blickem et al. (2013), Pickard and Rogers
(2012), and Vassilev et al. (2013), using the concepts to elaborate how the burden of
treatment was not a function of just the patient but of the patient’s familial and social
network and his or her community. In most cases, patients must find a support network
to help with the demand of the work of their disease and self-care.
Some patients endeavor to manage all of the treatments related to chronic disease
conditions, while other patients may not choose to maintain treatment regimens (May et
al., 2014). Although the best course for any patient would seem to be to follow treatment
regimens prescribed, patients have a variety of meaningful reasons for not doing so (May
et al., 2014). Financial issues play a major role in decisions about chronic care; a patient
may simply not be able to afford the cost of the treatments necessary to support his or her
illness (May et al., 2014). Other reasons noted by May et al. (2009) included an inability
to manage complicated and disruptive dosing schedules. In some cases, patients may
have such a wide variety of treatments and dosing schedules that he or she simply cannot
understand what medications are taken at any given time (May et al., 2014).
Alternatively, time may be a driving factor in determining whether to adhere to service
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and treatment schedules (May et al., 2014). Patients may not be able to take the time
from other life activities (e.g., work, family) in order to attend doctor or treatment visits
(May et al., 2014). Whatever the reason, choosing this path may lead to further decline
of health and increased need for even more costly treatments, creating a substantial
personal and public health burden by “wast[ing] of increasingly scarce healthcare
resources” (Mair & May, 2014, p. 1).
Eton et al. (2012) performed a qualitative study to begin the process of building a
patient-reported outcomes instrument to measure burden of treatment. Patients identified
for participation in the study were those who were medical outpatients at Mayo Clinic in
Rochester, MN and had agreed to participate in a medication management program (Eton
et al., 2012). All subjects had comorbidities that required significant management of
treatment, including ophthalmic conditions such as glaucoma and cataracts (Eton et al.,
2012). From this study, the researchers identified major themes and subthemes that were
used to inform the elaboration of burden of treatment theory and to develop a conceptual
framework for a pilot questionnaire pertinent to burden of treatment theory patientreported outcomes (Eton et al., 2012).
Tran et al. (2012) developed the first validated questionnaire that addressed the
burden of treatment for chronic illness across a multitude of chronic conditions and
treatment modalities. In this study, 502 subjects were included in validation of the
questionnaire that had been derived from literature review as well as from interviews
(Tran et al., 2012). The instrument took into account not only treatments for chronic
diseases but also the ancillary issues of disease surveillance, self-care, and lifestyle
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changes associated with increases in the burdens of disease and treatment (Tran et al.,
2012). The findings of the study provided further credence to burden of treatment theory
as a reliable conceptual framework for addressing chronic and debilitating diseases
experienced in aging populations (Tran et al., 2012).
Eton et al. (2013) looked at patient-reported measures of burden of treatment in
the three chronic diseases of diabetes, chronic kidney disease, and heart failure as a part
of their systematic review. Through the review of the available literature, Eton et al.
identified 57 patient-reported measures in 98 articles relevant to the evaluation of
treatment burden. The majority of the articles were identified from the diabetes
population, but measures were also identified in kidney disease and heart failure articles
that supported the need to evaluate other chronic diseases (Eton et al., 2013). This effort
was undertaken to determine how patient reported measures of treatment burden were
derived in disease categories and how best to incorporate prior work in the area into a
more reliable and comprehensive methodology for assessing the burden of treatment
across diseases (Eton et al., 2013). The work by Eton et al. expanded on the prior
qualitative analysis of treatment burden and was to be used in the further refinement of
the theoretical framework of burden of treatment theory.
Ridgeway et al. (2014) performed a qualitative study to evaluate factors that may
impact the burden of treatment for chronic conditions of diabetes, heart failure, and renal
failure. The aim of this qualitative study was to identify ways in which the burden of
treatment can be decreased for patients with multiple multimorbid conditions. Interviews
and focus groups were conducted that led to identifying major areas of burden and ways
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in which the study subjects were able to lessen their impact (Ridgeway et al., 2014). Five
major areas were identified as being associated with perception not only of treatment
burden but also successful management of that burden (Ridgeway et al., 2014). This
research clearly identified management strategies that increase the perception of control
over the disease and the corresponding treatment burden allowed patients to cope more
effectively and adhere to complicated and time-consuming treatment and service
regimens (Ridgeway et al., 2014).
May, Montori et al. (2009) and May et al. (2014) clearly described the criteria that
set apart diseases as burdensome. NAMD meets the criteria because it is a long-term,
debilitating disease and requires therapeutic management by a specialized healthcare
provider. Additionally, NAMD requires specialized treatments to forestall or prevent
progression. The burden of NAMD not only falls on the patient but also on the patient’s
network of friends, family, and caregivers in order to manage not just the burden of
illness (e.g., assistance with activities of daily living for prevention of comorbidities that
impact quality of life [QOL]) but also the burden of treatment (e.g., multiple visits to
physicians to receive complicated treatments; May et al., 2014). With this study, my goal
was to evaluate specific populations of NAMD patients treated with aflibercept to assess
whether health characteristic, treatment regimens used, and treatment outcomes differ
from what has been noted in prior literature. Additionally, I wanted to evaluate the
presence or absence of associations between health outcomes, treatment regimens, and
treatment outcomes to determine if the burden of treatment was being assigned to
appropriate populations.
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Age-Related Macular Degeneration
AMD is a progressive and chronic ophthalmic condition wherein changes to the
macula of the eye manifest and have an impact on visual function (Lim et al., 2012). The
macula is a small area near the center of the retina, and its health is necessary for
maintaining sharp, central vision that allows individuals to see directly ahead (NEI,
2015b). The early phase of AMD occurs when fatty deposits, drusen, collect in the
macula and present with a characteristically dry appearance (NEI, 2015b). Individuals
with this form of AMD do not typically report any significant vision loss, and the
condition is referred to as dry or atrophic AMD (NEI, 2015b). Intermediate AMD occurs
when the RPE displays changes that appear to be a disruption in the color or general
appearance of the RPE and/or drusen become larger creating more prominent changes in
visual function (NEI, 2015b). The late phase of AMD is characterized by either
increased atrophy in the RPE, choriocapillaris, and photoreceptors, known as GA, or the
development of new blood vessels into the choroidal space of the macula, known as CNV
(Lim et al., 2012). The physical changes in ocular vasculature seen in this phase are not
healthy structures and tend to leak blood, lipids, and other fluids into the surrounding
macular tissue causing a fibrous scar buildup (Lim et al., 2012). The late phase is
referred to as wet, exudative, or NAMD and is often related to increased levels of VEGFA secretion (NEI, 2015b). VEGF-A is “a diffusible cytokine that plays a key role in the
formation of CNV lesions through promotion of angiogenesis and vascular permeability”
(Rakic et al., 2013, p. 1850). NAMD and GA represent the foremost causes of blindness
in the world with an estimated global prevalence of 6.8% for early phase AMD and 1.5%
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for late phase AMD (Dawson et al., 2014; Lim et al., 2012; Rakic et al., 2013; Yuzawa,
Fujita, Tanaka, & Wang, 2013).
Based on a recent meta-analysis, Chakravarthy et al. (2010) identified risk factors
with a consistent and strongly positive association with AMD that included increased
age, cigarette smoking, cataract extraction, and family history of AMD. Other risk
factors with a consistent and moderately positive association included increased body
mass index, cardiovascular disease history, increased levels of plasma fibrinogen, and
hypertension (Chakravarthy et al., 2010). Lim et al. (2012) further noted hyperopic
refraction and sunlight exposure as significant risk factors.
An individual with NAMD or GA may not have been diagnosed with the early
forms of the disease previously, but may present to his or her physician with complaints
of straight lines becoming wavy or blank/hazy spots in the center of the visual field (i.e.,
metamorphosia) or the inability to see faces of people (Yuzawa et al., 2013). Once
identified by these complaints, an ophthalmologist will perform several ophthalmic
examinations to confirm the presence and extent of NAMD. These evaluations include
performing (a) BCVA testing, (b) dilated ophthalmoscopy, (c) Amsler grid testing, (d)
fluorescein angiography (FA), and (e) OCT (NEI, 2015b).
The manifestation of NAMD is not only loss of VA in the central field of vision;
there are concurrent impairments of color vision and contrast sensitivity (Yuzawa et al.,
2013). Patients with NAMD can often not distinguish colors clearly making it difficult to
read colored text, and the ability see the contrasts between light and dark may be
significantly impaired (Yuzawa et al., 2013). While peripheral vision is not impacted by
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NAMD, the loss of central vision is significantly disruptive to a patient’s activities of
daily living including recognizing faces, driving, and reading (Yuzawa et al., 2013).
Currently no treatments for the early or intermediate, dry forms of AMD exist,
rather intervention is focused on preventing progression to NAMD (Singer et al., 2012).
Watchful waiting, an understanding of the changes that might occur, and a plan of action
for changing vision along with nutritional support are the prophylactic means by which
individuals manage the earlier phases of AMD. As reported by the NEI (2015b),
nutritional support includes Vitamin C, Vitamin E, zinc (as zinc oxide), copper (as cupric
oxide), and beta-carotene or lutein and zeaxanthin. The standard of care treatment used
for advanced NAMD are injections with anti-VEGF drugs (e.g., ranibizumab,
bevacizumab, aflibercept) that are recombinant, humanized monoclonal antibody
fragments. These fragments neutralize active forms of VEGF-A, thereby inhibiting
proliferation of new blood vessels (Gower, 2012; Rakic et al., 2013). Anti-VEGF
injections are approved to be given intravitreally on a monthly basis for at least three
months (Kovach et al., 2012; Rakic et al., 2013). After that time, patients may receive
additional injections as determined by the ophthalmologist (Kovach et al., 2012).
Outcomes vary with anti-VEGF treatment; however, regaining up to 50% of the vision
lost in the initial onslaught of neovascularization and leakage has been reported when
damage is caught early (Lim et al., 2012).
Risk Factors Associated with NAMD
The risk factors most commonly associated with NAMD as have been elaborated
by The Foundation of the American Academy of Ophthalmology are age, genetic
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predisposition, environment, and behavior (The Foundation of the American Academy of
Ophthalmology, 2015). As this is the case, it is important to explore the known risk
factors to determine whether they are present in the identified patient populations to be
evaluated in this study. The risk factors section includes a description of racial/ethnic
factors, and comorbidities, genetic factors, and behavioral factors.
Racial/Ethnic Factors
NAMD has been characterized as a chronic condition largely affecting Caucasian
females (Coleman, Chan, Ferris III, & Chew, 2008). With the advent of better and more
abundant use of technology, such as FA, fundus photography, indocyanine green
angiography (ICGA), and OCT, an increase interest in determining whether this profile
still holds true has been generated (Coscas et al., 2014). Of special interest is whether
other types of populations, especially Asian populations, are similar to or different from
Caucasian populations with regard to risk and prevalence of AMD (Coscas et al., 2014;
Nakata et al., 2013; Wong et al., 2014). In a study performed by Nakata et al. (2013), the
Nagahama study, which was a community based, cross-sectional, prospective cohort
study, the investigators evaluated the prevalence and characteristics Japanese patients
with early and late AMD. The study included 5,595 Japanese individuals aged greater
than or equal to 50 year of age with gradable AMD recruited from 2008 to 2010 (Nakata
et al., 2013). Similar rates of early AMD were observed in this Japanese population as
compared to Caucasian populations (Nakata et al., 2013). As well, similar rates of late
AMD were observed in this Japanese population as compared Caucasian populations in
individuals less than 70 years of age (Nakata et al., 2013). At age 70 and higher, the rate
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of AMD decreased in this Japanese population and was considered to be significantly
lower than in Caucasian populations (Nakata et al., 2013). Findings of differences in
early or late AMD between males and females were not apparent (Nakata et al., 2013).
In a later retrospective review performed by Coscas et al. (2014), the authors
evaluated both technology used to assess patients for NAMD and prevalence of subtypes
of NAMD (i.e., AMD with Type 1 CNV, AMD with Type 1 and 2 CNV, AMD with
Type 2 CNV, chorioretinal anastomosis, polyploidal choroidal vasculopathy [PCV]
without CNV, and PCV with Type 1 or 2 CNV) in 94 French and 99 Japanese patients
with presumed exudative AMD. PCV was found to be at a higher rate in Japanese
patients, and Type 1 CNV was found to be at a higher rate in French patients (Coscas et
al., 2014). Similarities were noted in Type 2 CNV and chorioretinal anastomosis rates
between the two populations (Coscas et al., 2014).
Wong et al. (2014) integrated a large number of population-based AMD studies
that previously suggested different disease prevalence based on racial or ethnic
parameters. By identifying qualified population-based studies using a systematic
literature review, these investigators analyzed “129,664 individuals (aged 30-97), with
12,727 cases from 39 studies” (Wong et al., 2014, p. e106). This large review indicated
that the global burden of all types of AMD is 8.7% (Wong et al., 2014). The projection
for the number of cases in 2020 was estimated at approximately 196 million and by 2040,
the estimate was approximately 288 million (Wong et al., 2014). The prevalence of early
onset AMD was shown to be higher in studies based on European populations than in
Asian populations; however, late stage AMD prevalence comparison between these two
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groups was similar (Wong et al., 2014). The findings from the studies analyzed,
however, did not consistently show whether the diagnoses included PCV, which is more
prevalent in Asian populations and may respond differently to treatment (Wong et al.,
2014). Females of any race were not found to have a strong association with prevalence
of AMD, and strong evidence refuted previously reported findings that male, Asians who
smoked were at higher risk than other populations (Wong et al., 2014). Finally, Wong et
al. suggested that Asian countries will see the highest increase in all forms of AMD in the
future despite having a low reported prevalence for the period investigated.
The findings from these studies are significant for several reasons. Future
research should include a significant contribution of patients from Asian populations to
represent all aspects of the NAMD disease process (Coscas et al., 2014; Nakata et al.,
2013; Wong et al., 2014). Physicians should be aware that the prevalence of AMD in
Asian populations approaches that of Caucasian populations in order to provide proper
diagnosis and treatment (Coscas et al., 2014; Nakata et al., 2013; Wong et al., 2014).
Differentiating subtypes through the use of available technology could lead to a
difference in treatment (Coscas et al., 2014; Nakata et al., 2013; Wong et al., 2014).
Comorbidities
Due to the specialty area that ophthalmology has become, Cheung and Wong
(2014) noted that AMD has been thought of as a localized disease with an association
with certain risk factors (e.g., smoking, prior cataract surgery, family history). AMD has
not been assessed in relation to comorbidities of the whole individual (e.g., hypertension,
dyslipidemia, cardiovascular disease; Cheung & Wong, 2014). Based on information
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from Chou et al. (2013) and Cheung and Wong, assessing the whole patient in relation to
comorbidities and association with the risk of AMD is a reasonable approach.
Chou et al. (2013) performed an analysis on 2012 National Health and Nutrition
Examination Survey (NHANES) data to determine the source of age-related conditions
associated with visual impairment among U.S. adults. The analysis included 5,222
individual included in the 2012 NHANES who were 40 years of age or older (Chou et al.,
2013). From this analysis, the investigators were able to determine the prevalence of
visual impairment was 7.5% and prevalence of visual impairment not due to refractive
error was 2.5% (Chou et al., 2013). These findings suggest an estimated population of 9
million adults in the United States over the age of 40 have some visual impairment (Chou
et al., 2013). While a significant portion of the study population whose visual
impairment could be corrected simply by providing proper refractive correction, of
greatest concern was the 25% of visual impairment attributed to factors other than
refractive error (Chou et al., 2013). Chou et al. reported AMD to be the most commonly
associated with visual impairment not related to refractive error.
Cheung and Wong (2014) performed an extensive literature review of articles
published from January 1, 2012 through December 31, 2013, examining various systemic
risk factors to determine which were most highly associated with increased risk of AMD.
An interesting aspect of the evaluation was that the assessment was originally concerned
with determining what systemic conditions increased the risk of AMD; however, a
corollary that AMD may be an indicator of potential manifestation of systemic disease
was revealed during this investigation (Cheung & Wong, 2014). The systemic diseases
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or conditions found to be most highly associated with increased risk of AMD were
cerebrovascular disease and coronary heart disease (Cheung & Wong, 2014).
Hypertension and dyslipidemia were shown to have a moderate association with
increased risk of AMD but the strength and consistency of the association was not as
apparent from the review of literature (Cheung & Wong, 2014). Evaluation of the
potentially correlated systemic risk factors was suggested to be of importance in
identifying patients at risk for developing NAMD (Cheung & Wong, 2014).
Systemic therapies were also evaluated by Cheung and Wong (2014).
Antioxidant supplements such as those found in the AREDS formulations were found to
result in a reduction in intermediate AMD to advanced AMD by approximately 25% over
approximately 6 years (Cheung & Wong, 2014). Aspirin used prophylactically for
cardiovascular disease may actually increase the risk of AMD although the mechanism of
the potential increase was not clearly understood (Cheung & Wong, 2014). Use of statins
has not been shown to reduce the risk of or progression of AMD consistently in the
literature (Cheung & Wong, 2014).
These investigations lend further credence for the need to ascertain whether
NAMD population treated with anti-VEGF differ with regard to comorbidities and
whether an association exists with a difference in treatment outcome. While aging has
been clearly associated with AMD, subjects with prevalent comorbidities associated with
immune response would typically be excluded from clinical trials to minimize the issue
of confounding factors. While it may not be acceptable to include subjects with
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significant systemic comorbidities in early clinical trials, later phase clinical trials should
examine the impact of intervention when significant systemic comorbidities are present.
Genetics
Inroads into the understanding of genetic factors associated with NAMD were
slow moving until 2005 with the identification of complement factor H (CFH) that was
determined to increase the risk of NAMD significantly (Fritsche et al., 2014). From this
beginning, an explosion of research led to the identification of at least 19 alleles
associated with genetic predisposition for NAMD (Fritsche et al., 2014). With these
findings come the prospect of advances not only in understanding of AMD but also of
more and better treatments for all phases of the disease (Fritsche et al., 2014).
Hagstrom et al. (2013) evaluated 834 (73%) of the subjects who participated in
the Comparison of AMD Treatment Trial (CATT) at 43 of the CATT clinical sites.
These investigators enrolled the identified subjects in a clinical trial to determine whether
subjects of differing genotypes had different responses to the anti-VEGF therapies,
ranibizumab and bevacizumab. Each of the subjects “was genotyped for [single
nucleotide polymorphisms] rs1061170 (CFH), rs10490924 (ARMS2), rs11200638
(HTRA1), and rs2230199 (C3)” (Hagstrom et al., 2013, p. e43). These alleles have been
noted to have potential impact on the development of AMD; however, no statistically
significant differences were noted in any of the clinical assessments measured based on
the genotypes studied, including in the instance of multiple alleles that were present in
any individual subject (Hagstrom et al., 2013).
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Nussenblatt et al. (2014) provided investigation into the genetic components of
AMD and reported, “recent genetic meta-analysis has confirmed 19 loci…that account
for up to 50% of the heritability of AMD susceptibility” (p. 6). This finding along with
environmental factors (e.g., smoking, diet, and weight) “play a crucial role in AMD
etiology” (Nussenblatt et al., 2014, p. 6). Further, Nussenblatt et al. noted that both
genetic and environmental issues need to be considered in the context of aging, as aging
remains the primary risk factor for AMD. An aging immune system, or
immunosenescence, accounts for an increased production of inflammatory cells and a
decreased ability to clear these types of cells (Nussenblatt et al., 2014). As such, the
immune system becomes overloaded and cannot maintain a homeostatic state within the
body, or specifically the eye (Nussenblatt et al., 2014). The research by Nussenblatt et al.
further supports the assertion that AMD is not an isolated disease process but rather is a
localized manifestation of the immunosenescence of the aging body.
Cheung and Wong (2014) also noted that genetic markers and pathogenesis
support the hypothesis that AMD is more than a localized condition. Inflammation may
play an important role in the pathogenesis of AMD (Cheung & Wong, 2014). CFH and
age-related maculopathy susceptibility 2/HtrA serine peptidase 1 genes have been noted
to be associated with AMD. Cheung and Wong concluded, “there is accumulating
evidence to support the concept that AMD is a localized ocular manifestation of broader
systemic processes and is closely associated with a range of systemic diseases” (p. 148).
As a result of the aforementioned studies, the importance of gathering and
analyzing genotype information in clinical practice and clinical research was established.

38
Collecting genotype information for NAMD patients adds complexity to patient or
subject visits. As well, the cost of the testing may prohibitive. However, the benefit of
clearly understanding the genetic basis of the disease to develop more appropriate and
targeted treatments is critical to eradicating this debilitating disease.
Behavioral Risks
Behavioral factors that may increase risk of AMD have been enumerated by The
Foundation of the American Academy of Ophthalmology (2015) and include smoking,
overexposure to sunlight, and diet. While smoking and overexposure to sunlight have
been included in clinical trial investigations for quite some time, the issue of diet is more
difficult to evaluate. That stated, a number of investigators have endeavored to evaluate
the link between AMD and dietary intake (Amirul Islam et al., 2014; Arnold, Jentsch,
Dawczynski, & Böhm, 2013; Chiu et al., 2014; Christen et al., 2012).
Christen et al. (2012) performed a long-term, prospective study in physicians to
determine if Vitamin E and Vitamin C had an impact on the development of AMD.
Subjects in this study were randomized to either intervention with a regimen of Vitamin
E and Vitamin C or to a regimen of placebo. Subjects were asked to report on an annual
basis regarding the development of AMD (Christen et al., 2012). If an AMD diagnosis
was reported, medical records were reviewed to confirm the self-report (Christen et al.,
2012). After 8 years of evaluation, no differences were found between the incidence of
AMD in the two groups suggesting that Vitamins E and C were neither harmful nor
beneficial to the development of AMD (Christen et al., 2012).
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Arnold et al. (2013) performed a pilot study to determine if a diet high in
oleaginous extract of Brassica oleracea var. sabellica L. (kale) could impact
concentration of xanthophyll in both plasma and the macula. An inverse risk has been
suggested to exist between xanthophyll concentration and AMD (Arnold et al., 2013).
Twenty subjects were enrolled in this well-designed and controlled study (Arnold et al.,
2013). Subject participation included both an intervention period and a washout period
after intervention (Arnold et al., 2013). While both plasma and macula levels of
xanthophyll were elevated during the intervention portion of the study, the effect was not
present after the 4-week washout (Arnold et al., 2013). This led Arnold et al. to surmise
that the “distribution of the xanthophylls in the macula seems to be more dynamic than
originally assumed” (p. 1412). In order to maintain a high level of xanthophylls,
consumption of kale and other xanthophyll-containing foods would need to be kept at a
continuously high level (Arnold et al., 2013).
Amirul Islam et al. (2014) attempted to discover specific dietary intake patterns
associated with the risk of developing AMD based on primary food intake scale (F1 =
fruits, F2 = vegetables, F3 = grains, fish, boiled or steamed chicken, and nuts, F4 = red
meat, F5 = processed foods, and F6 = salad). No clear delineation of specific food types
was found to be associated with a higher risk of AMD. An association with decreased
risk of AMD seemed to be indicated in subjects with diets higher in fruits, vegetables,
chicken and nuts than in those with diets higher in red meat consumption (Amirul Islam
et al., 2014).
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Chiu et al. (2014) hypothesized that the American dietary pattern put individuals a
higher risk for the development of AMD. In a cross-sectional study of subjects
participating in the AREDS study, Chiu et al., classified 8,103 eyes per the AMD
classifications developed by AREDS. These included 2,739 subjects without AMD who
served as the control group, 4,599 subjects with early AMD, and 765 with late AMD. By
evaluating the diets of these subjects, Chiu et al. identified two main dietary types (i.e.,
Oriental and Western) based on the principal components consumed. Subjects who
consumed more fresh fruits, vegetables, and fish were considered to follow an Oriental
dietary pattern (Chiu et al., 2014). Those subjects who consumed more processed,
refined, high fat foods and red meat were considered to follow a Western dietary pattern
(Chiu et al., 2014). The findings indicated that both dietary patterns are associated with
early or late AMD (Chiu et al., 2014). The subjects who consumed food according to an
Oriental pattern showed reduced odds of developing AMD, with the more adherent
subjects gaining additional protection (Chiu et al., 2014). The subjects who consumed
food according to a Western pattern showed increased odds of developing AMD, with
additional risk associated with greater consumption of a Western diet (Chiu et al., 2014).
The findings from these studies are widely varied from direct support for dietary
impact on both increasing and lowering risk of AMD to no clear support for either a
beneficial or harmful impact on the development of AMD. The absence of clearly
understood mechanisms suggests an importance exists in understanding what type of diet
patients typically consume to find additional means for lowering the burden of this
disease. Collecting information pertaining to weight or dietary intake in ophthalmic
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clinical practice or clinical research is atypical. Consequently, coordination between
several medical disciplines would be necessary to integrate dietary patterns with
ophthalmic findings.
Treatments for NAMD
Treatment of NAMD was exceedingly limited until the relatively recent
therapeutic approvals of anti-VEGF treatments (Wang & Ohji, 2013). In the 1980s, the
treatment option was argon laser photocoagulation (Stein et al., 2013). For this
procedure, argon laser was applied to the lesion in the macula, which destroyed the tissue
but stopped the leakage and destruction of macular cells by essentially cauterizing the
lesion (Stein et al., 2013). Continued visual loss was typically ameliorated, but no VA
gains were evident, and a risk of iatrogenic vision loss was apparent (Stein et al., 2013).
In 2000, the FDA approved photodynamic therapy (PDT) with verteporfin
(Visudyne) indicated for subfoveal choroidal neovascularization treatment (Stein et al.,
2013). Treatment consisted of the injection of verteporfin intravitreally activated by
exposure to a laser light source in order to cause occlusion of the neovascularization in
the macula (Curtis et al., 2012). As with argon laser photocoagulation, PDT can stop the
progression of neovascularization but does not restore vision lost by the initial growth of
vessels into the macula (Curtis et al., 2012).
Treatment for NAMD has changed dramatically over the past 12 years with the
approval in 2004 of the first of the anti-VEGF treatments, pegatinib (Macugen), and
approval of ranibizumab (Lucentis) followed in 2006 and aflibercept (Eylea) in 2011
(Stein et al., 2013). Although not approved for NAMD, bevacizumab (Avastin) has also
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been used in for NAMD treatment due to its identification as a much less costly
alternative the anti-VEGF treatments approved for treatment of NAMD (Stein et al.,
2013). With the advent of anti-VEGF therapy, no longer was the treatment modality one
of stopping progression as with PDT; anti-VEGF treatment offered patients the hope of
regaining some of the vision that had been previously lost (Curtis et al., 2012). AntiVEGF therapy utilizes recombinant, humanized monoclonal antibody fragments to
neutralize active forms of VEGF-A present in the affected, thereby inhibiting
proliferation of new blood vessels (Curtis et al., 2012). Patients experience an
amelioration of progressive vision loss as well as a recovery of vision over the course of
continued injections (Curtis et al., 2012).
Yannuzzi, Patel, Bhavsar, Sugiguchi, and Freund (2014) performed a crosssectional, physician survey to determine if anti-VEGF treatments had a negative impact
on intraocular pressure (IOP). The study conducted was limited in that it was a crosssectional study, and the prevalence of sustained IOP increases were reported by the
physicians and were not objectively reported by means of IOP data submission and
analysis (Yannuzzi et al., 2014). Nonetheless, the findings were interesting in that the
investigators were able to determine that “higher injection volumes [of anti-VEGF] with
a rapid injection technique may potentially lead to sustained IOP elevation” (Yannuzzi et
al., 2014, p. 319). Utilizing treatment regimen or treatment techniques that are not
supported by clinical research may lead to negative outcomes in visual function and other
aspects of ophthalmic disability.
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Concern has also been expressed regarding the potential for anti-VEGF therapies
used to treat NAMD to increase risk of negative cerebrovascular and cardiovascular
effects (Cruess & Giacomantonio, 2014). This concern came about with the off-label use
of bevacizumab for NAMD and was based at least in part on the systemic findings of the
anti-VEGF class of drugs (Cruess & Giacomantonio, 2014). The systemic findings
centered around the impact that anti-VEGF therapy had on VEGF in systemic circulation
that decrease the patency of vessel walls and may cause vessel leakage and destruction of
tissues (Semeraro et al., 2014). Thus, investigations were initiated into the issue with
interesting findings that do not necessarily support the concern for ophthalmic use of
anti-VEGF treatment. Semeraro et al. (2014) expressed the concern that intravitreal
injection with anti-VEGF could have an impact on circulating VEGF systemically;
however, the evaluation of clinical studies performed by these investigators did not
support an association between the use of anti-VEGF therapies intravitreally and an
increased incidence of thromboembolitic events (Semeraro et al., 2014). The incidence
of cerebrovascular accident, myocardial infarction, and death was similar in both treated
and untreated subjects observed (Semeraro et al., 2014).
Similarly, Ng et al. (2015) expressed concern regarding the use of anti-VEGF
treatments. These investigators, too, communicated that although no signals had been
found to support concern in the products approved for intravitreal injection for NAMD,
the same could not be said for bevacizumab as it had not been evaluated in the same
manner as the anti-VEGF treatments approved for NAMD treatment. As has been
mentioned, bevacizumab is not approved for intravitreal injection to treat NAMD but is
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often used off-label due to the lower cost of the product. Ng et al. evaluated a large
cohort of subjects who had been treated predominantly with bevacizumab. The results
from the analysis of these subjects supported the same conclusions as those of Semeraro
et al. (2014); no association between the use if intravitreal bevacizumab and increased
risk of cerebrovascular or cardiovascular events or death was found (Ng et al., 2015).
Aflibercept Dosing Regimen and Outcomes
Specifically in NAMD populations, studies of all phases are often performed in
treatment naïve subjects in order not to have prior treatments obfuscate the findings in the
trial under investigations (Christen et al., 2012; Gambon et al., 2014; Mazaraki,
Fassnacht-Riederle, Blum, Becker, & Michels, 2015; Rush, Rush, Aragon II, & Ysasaga,
2014; Tan et al., 2013). While approaching clinical studies in this manner may lead to a
clearer understanding of the mechanisms underlying certain treatments, unless these same
types of studies are performed in subjects who have been exposed to NAMD treatments,
there is a knowledge burden that will be faced by the NAMD population that is not naïve
to anti-VEGF treatments. External validity of the clinical research study has been
sacrificed for internal validity. The ability of an NAMD patient treated with multiple
therapies and his or her physician to make appropriate treatment decisions is hampered
by the lack of knowledge about how this additional therapy might impact the patient’s
health and wellbeing.
FDA approval for the aflibercept was predicated on two Phase 3, multicenter,
randomized, active-controlled, clinical trials in which a total of 2,419 subjects were
randomized to one of the following study arms:
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•

0.5 mg intravitreal aflibercept dosed monthly

•

2 mg intravitreal aflibercept dosed monthly

•

2 mg intravitreal aflibercept dosed every 2 months after 3 initial monthly
doses

•

0.5 mg intravitreal ranibizumab dosed monthly (Heier et al., 2012)

The primary visual outcome used to evaluate the efficacy of aflibercept in NAMD was
proportion of subjects who maintained gains in BCVA by ETDRS logMAR scoring
assessed 52 weeks after treatment (Heier et al., 2012). Anatomical features such as CNV
lesion size and central retinal thickness were also considered significant outcome
measures (Heier et al., 2012). Aflibercept was required to meet a noninferiority standard
of no less than 10% difference from ranibizumab outcomes (Heier et al., 2012). All
aflibercept study arms were considered to be as effective in improving BCVA and
preventing BCVA loss as ranibizumab (Heier et al., 2012). Additionally, similar results
were detected with regard to anatomic measures (Heier et al., 2012). As a result, the dose
of aflibercept recommended and approved was “2 mg (0.05 mL or 50 microliters)
administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3
months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2
months)” (FDA, 2011, sec. 2.2). This protocol, then, is the standard by which
populations should be judged when evaluating the safety and efficacy of aflibercept in a
realistic analysis of clinical practice.
Both the issue of knowledge burden and confounding may apply to the issue of
racial diversity in clinical trials. As has been noted previously by Coscas et al. (2014),
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Nakata et al. (2013), and Wong et al. (2014), a genetic difference between Caucasian and
Asian patients with NAMD seemed to exist. Although race is collected in clinical trials,
the use of this information is not supportive of the translation of prior epidemiological
studies of these populations into clinical trials (Thornicroft, Lempp, & Tansella, 2011).
Statisticians may analyze race between randomized groups in a study to show whether or
not differences occurred between the numbers and types of individuals randomized to
each group (Kessler & Glasgow, 2011). Whether race is then analyzed as a subgroup that
might have an impact the outcomes seen based on the use of the investigational product is
unclear. Because analyses of race/ethnicity and outcome are not conducted, a knowledge
burden for patients and physicians is produced for determining the best treatment options
as the potential confounding effect of race has not been adequately investigated. The
possibility exists that a patient may be treated with a product that is not particularly
effective based on the patient’s race (Coscas et al., 2014; Nakata et al., 2013; Wong et al.,
2014). This increases the burden on the patient both financially and functionally, since
the visual outcome might not be optimal (Muether, Hermann, Koch, & Fauser, 2011).
Further, it places an increased burden on healthcare and public health systems, since
optimal visual function outcomes have not been met and additional outlay of public funds
may be necessary to support the increased disability of the patient due to blindness
(Muether et al., 2011; Schmier et al., 2012).
Rakic et al. (2013) noted that realistic clinical practice outcomes for patients who
were treated with ranibizumab showed both initial and continuing improvement in a
prospective, multicenter, observational study of open-label treatment with 0.5 mg of
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ranibizumab according to realistic clinical practice conditions. The realistic clinical
practice paradigm effectively means that the treatment regimen was according to the
FDA labeling for ranibizumab and not proscribed by a protocol different from the
labeling (Rakic et al., 2013). A total of 267 subjects were initially treated in the study
and were followed for up to 24 months (Rakic et al., 2013). Investigators were asked to
follow the normal procedures of treatment, document procedures in medical records,
request completion of QOL questionnaires by enrolled subjects, and schedule standard
follow-up visits at 6, 12, and 24 months, which is usual in this indication (Rakic et al.,
2013). The investigators were asked to follow the treatment regimen recommended by
the labeling of ranibizumab, which includes monthly injections of 0.5 mg ranibizumab
for the first 3 months followed by monthly BCVA checks and additional injections based
on the visual outcome findings (Rakic et al., 2013). As noted by Rakic et al., (2013), the
mean number of injections delivered during the loading phase did approximate that noted
in the labeling (2.5 ± 0.7 injections over 2.5 ± 2 weeks). This mean, however, does not
completely depict what transpired with subjects. Specifically, about half of subjects
(52.6%) received all three injections, 39.2% received two injections, and 8.2% received
one injection in the first 3 months (Rakic et al., 2013). During the follow-up phase of the
study over the remaining 21 months, re-injection was based on findings of the visual
outcomes assessments (Rakic et al., 2013). If the physician diagnosed progression of
NAMD, additional injections were given (Rakic et al., 2013). If no progression was
present, the subject did not receive additional injections (Rakic et al., 2013). This
treatment paradigm does differ from that of several of the large, pivotal trials that

48
substantiated the approval of ranibizumab wherein subjects were treated monthly for
approximately 12 months. By using the labeled treatment regimen, Rakic et al. (2013)
noted that the number of injections was significantly lower than that of the clinical trial
treatment regimen (5.9 ± 3.6 injections over 11.5 ± 9.5 weeks). These more variable
treatment conditions based on observation and clinician judgment did lead to positive
visual outcomes, but the outcomes were not as strongly positive as had been
demonstrated in the approval-based clinical trials that used a protocol of monthly
injections (Rakic et al., 2013).
In an evaluation of the outcomes from a retrospective review of data presented by
Holekamp et al. (2014), the authors evaluated a large claims database to determine if the
methods elaborated for treatment regimen in randomized, controlled trials (RCTs) were
used in clinical practice. For the anti-VEGF treatments available at the period of time
investigated, the treatment regimen advocated based on RCTs was monthly monitoring
and frequent intravitreal injection to maintain the best visual outcomes, which translated
to approximately monthly injections with anti-VEGF treatment in the RCTs (Holekamp
et al., 2014). This study evaluated over 19,000 patients with claims based on new
diagnoses. The findings for the period investigated (i.e., 2006–2007) for ranibizumab
and bevacizumab use were quite different from what had been shown to be safe and
effective in RCTs. Rather than the twelve injections supported by the approval-based
clinical studies, patients received a mean annual number of 4.6 injections in the
bevacizumab-treated group and 6.9 injections in the ranibizumab-treated group.
(Holekamp et al., 2014). Further, these patients received substantially fewer follow up
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clinic visits to assess visual outcomes and adjust treatment as needed. Although these
investigators were not able to determine the direct effect on visual outcomes based on
their use of the claims data, almost certainly an addition burden was placed on patients
who were not treated according to the established treatment regimen (Holekamp et al.,
2014).
Translating procedures and findings from both clinical trials and epidemiological
studies to clinical practice is a change that needs to occur in our healthcare paradigm for
the best outcomes for patients and physicians. The level of clinical care provided by the
investigators evaluated in Rakic et al. (2013) seems to have surpassed that of those
evaluated in Holekamp et al. (2014). This difference would suggest a decline in
outcomes would be more profound as noted by the information provided by Rakic et al.
(2013).
Summary
Aflibercept treatment has been approved for marketing in NAMD patients by the
FDA; however, the use of this intervention and outcomes associated with its use in
populations that differ from the clinical research population have not been wellcharacterized. In this study, my goal was to evaluate whether differences existed
between three retinal practice populations of NAMD patients treated with aflibercept
with regard to selected health characteristics, treatment regimens, and treatment
outcomes. A secondary analysis evaluated associations between the selected variables.
The literature reviewed supported that several different variables (i.e., race/ethnicity,
comorbidities, genetic factors, and behavioral factors) were associated with an increased
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risk of NAMD but may not be evaluated in NAMD clinical trials. As well, the literature
review supported the need for examination of different population centers to determine if
differences or associations existed between the populations with regard to selected health
characteristics, treatment regimens, and treatment outcomes. The research methodology
employed could help to fill a gap in the literature related to the aflibercept treatment
regimens and outcomes and could extend the body of knowledge pertaining to aflibercept
treatment and NAMD outcomes in a variety of populations. I will discuss the
methodology for this study in Chapter 3.
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Chapter 3: Research Method
Introduction
In this study, I evaluated three geographically disperse private retinal practices to
determine if differences between NAMD patients treated with aflibercept existed, and
secondarily, whether associations regarding selected health characteristics, treatment
regimens, and treatment outcomes existed. In this chapter, I will provide details of the
specifics for the research methodology used, including the research design and rationale,
target population, sample and sampling procedures, and data collection procedures. I will
also elaborate the operationalization of all variables in the study, the data analysis plan,
and any threats to the validity of the study. Finally, I will review ethical considerations
and the implications of these on the data collection method.
Research Design and Rationale
In this study, I used a retrospective, cross-sectional study design wherein the
categorical groups of NAMD patients treated with aflibercept from three geographically
disperse private retinal practices (grouping variable) were contrasted with respect to
demographic and selected health characteristics (independent variables), treatment
regimens (independent variables), and treatment outcomes (dependent variables). As
noted by Frankfort-Nachmias and Nachmias (2007), using contrasting groups creates a
situation wherein “straightforward comparative statistical analyses” (p.119) can be
performed on the various dependent variables under observation. Campbell and Stanley
(1963) clarified that contrasting group research is not the same as the pretest-posttest
control group design in that subjects in a contrasting group project could not be randomly
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assigned to the categorical groups described. For this study, I used categorical groups
rather than the randomization of subjects since both the primary objectives involved
categories by which the groups are naturally divided and into which individuals could not
be randomized (Campbell & Stanley, 1963; Frankfort-Nachmias & Nachmias, 2007). I
collected the data for this study by traveling to one of the retinal practices to work
directly with the personnel who manage the EMR system. For the other two practices,
the data were available by direct access to the EMR system. By using direct interaction
with the selected retinal practices, I gathered the most appropriate information in the most
efficient manner. Time constraints were a limiting issue for the personnel at the retinal
practices with a direct impact on the timeliness of gathering data. Travel costs were also
prohibitive in gaining access to data at the physician’s practice that was in California.
The result was that data for fewer subjects were made available at this practice.
Population
The population for this study included patients identified at participating retinal
centers who had a diagnosis code in ICD-9 of 362.52 (exudative senile macular
degeneration of retina). Specifically, I included patients in the study from three retina
centers located in three population centers in the United States, based on review of EMR,
if they meet the following criteria:
•

Diagnosis of NAMD in at least one eye during the period of 2011 to 2014.

•

Treatment with aflibercept intravitreal injections after approval in 2011.

•

At least one BCVA and OCT assessment within the approximately 1-month
period prior to treatment with aflibercept.
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•

At least three BCVA and OCT assessments during the approximately 1-year
period following treatment with aflibercept.
Sampling and Sampling Procedures

I used a one-way ANOVA to evaluate continuous variables (i.e., age, number of
ocular and systemic comorbidities, number of days between initial NAMD diagnosis to
the first aflibercept treatment, baseline VA, baseline OCT, the average number of days
between treatments, the average number of treatments giving during the approximately 1year period following the first aflibercept treatment in the study eye, change from
baseline VA, and change from baseline OCT) to determine whether differences were
present between the three geographically disperse retinal practices. c2 analysis was used
to evaluate the categorical variable of gender to determine if differences existed in this
variable between the three retinal practices. Associations were evaluated using
Spearman’s rank-order correlation for the comparison of two continuous variables and
point-biserial analysis for comparison of the combination of categorical and continuous
variables. When assumptions were violated, I performed the appropriate nonparametric
testing as deemed appropriate. This included using a Welch one-way ANOVA with post
hoc testing for variables in which the homogeneity of variance assumption was violated.
As noted by Sheperis (2013), most researchers accept a power of 0.80 (80%)
when determining sample size estimates; however, clinical research studies typically
depend on a power of .90 to .95 (90% to 95%) for studies for which FDA approval for
marketing is sought. The proposed analysis for this study was based on 95% power
calculation. With this information and estimating a modest effect size of 0.25, a sample
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size of 252 participants and two degrees of freedom in the numerator and 249 degrees of
freedom in the denominator resulted in 95.1% chance of detecting a statistically
significant difference between the three groups (i.e., retinal practices) at a = 0.05 using a
fixed effects, omnibus, one-way ANOVA. The sample size estimate was calculated
using G*Power, version 3.1.9.2 (Faul, Erdfelder, Buchner, & Buchner, 2007).
I chose a purposive sampling method for the general NAMD patient population in
order to capture data for all patients identified within the period specified previously at
each of the retina specialists’ offices. Each site provided a de-identified data set with the
appropriate patients included. Since three retinal practices were identified, the sample
was proposed to be divided by the number of practices and data from approximately 84
patients was to be collected at each site (N = 252). Patients were: (a) identified working
from the most recently diagnosed patients, (b) with at least one year of follow-up, (c)
starting at 2015 and working backward in time until the appropriate number of patients
had been identified. The proposed accrual was a total of 84 patients identified at each
site.
Procedures for Recruitment, Participation, and Data Collection
For the general NAMD population, three retinal specialist sites located in various
geographic locations within the United States gave me permission to review patient EMR
under strict adherence to Health Insurance Portability and Accountability Act (HIPAA)
of 1996 rules pertaining to the privacy of patient medical information. I conducted my
review to identify those patients at the retinal practices who met the first of the criteria
(i.e., having NAMD diagnosis in at least one eye during the period of 2011 to 2014).
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Once appropriate patients were identified within the EMR database, I separated those
patients who met the remaining criteria from the whole of the EMR records for deidentification. Only those fields necessary for analysis were collected. Fields that were
not captured in the final database included: name, work place name, personal and work
addresses, personal and work telephone numbers, personal and work e-mail addresses,
insurance, and any other information that might lead back to the individual’s
identification. Due to the retrospective nature of this study and the fact that patient
information was de-identified, there was no need for me to collect informed consent for
use of the data.
Operationalizing Variables
To operationalize the data, a definition of each of the variables was necessary.
The variables that I proposed to collect in the general population dataset are described in
greater detail in Table 1.
Table 1
Planned Variables and Coding for General NAMD Population
Variable

Definition

Nature of

Coding of Variable

Variable
Patient ID

De-identified

Text

Site 1 = 1001 – 1999

Patient

Site 2 = 2001 – 2999

Identification

Site 3 = 3001 – 3999

Number
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
Gender

Patient’s Gender

Dichotomous 1 = Male
2 = Female

Race/Ethnicity

Patient’s reported
race or ethnicity

Categorical

1 = White
2 = Black or African
American
3 = Hispanic or Latin
4 = American Indian and
Alaska Native
5 = Asian
6 = Native Hawaiian and
Other Pacific Islander
7 = Multiple Race/Ethnicity
(check all that apply)
1 = White
2 = Black or African
American
3 = Hispanic or Latin
4 = American Indian and
Alaska Native
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
5 = Asian
6 = Native Hawaiian and
Other Pacific Islander
Age

Age in years

Numeric

__.__ years

calculated from
the date of birth
compared to the
date of the dataset
Iris Color

The predominant

Categorical

1 = Gray

color of the iris in

2 = Blue

each eye

3 = Green
4 = Hazel
5 = Brown
6 = Black
7 = Other
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
Ocular

Does the patient

Categorical

1 = Cataract

Comorbidities

have any of the

2 = Cytomegalovirus Retinitis

following ocular

3 = Diabetic Macular Edema

comorbidities?

4 = Glaucoma or Ocular

(check all that

Hypertension

apply)

5 = Keratoconus
6 = Posterior Vitreous
Detachment
7 = Retinal Detachment
8 = Retinal Vein Occlusion
9 = Uveitis
10 = N/A

Systemic

Does the patient

Comorbidities

have

2 = Digestive

comorbidities

3 = Endocrine

associated with
any of the
following body

Categorical

1 = Circulatory

4 = Immune
5 = Integumentary
6 = Muscular
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
systems? (check

7 = Nervous

all that apply)

8 = Reproductive
9 = Respiratory
10 = Skeletal
11 = Urinary
12 = N/A

Comorbidities

If yes, diagnosis
associated with
body system

Text

Text entered in this field will
be coded based on the Medical
Dictionary for Regulatory
Activities (MedDRA).

Smoking

Does the patient
report a history of

Dichotomous 1 = No
2 = Yes

smoking?
Alcohol Abuse

Does the patient
report a history of

Dichotomous 1 = No
2 = Yes

alcohol abuse
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
Genotype

Does the

Categorical

physician report

1 = rs11200638 of the HTRA1
gene

either of the

2 = rs10611710 of the CFH

genotypes for the

gene

patient?

3 = Other
4 = N/A

Eye Involved

Diagnosis Date

Which eye(s)

Categorical

1 = OD

have a diagnosis

2 = OS

of NAMD

3 = OU

Date the patient’s

Date

ophthalmologist

ODDiag = DD MON YYYY
OR

diagnosed

OSDiag = DD MON YYYY

NAMD for each

OUDiag = DD MON YYYY

eye
Length of

Calculated from

Numeric

ODLength = __.__ years

Diagnosis

the date of

OSLength = __.__ years

diagnosis to the

OULength = __.__ years

date of the dataset
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
Dates of

Aflibercept

Treatment

treatment dates

Date

ODTrt1 = DD MON YYYY
OR

for the study eye

OSTrt1 = DD MON YYYY
OUTrt1 = DD MON YYYY

Study Eye

The eye which

Categorical

received the first

1 = OD
2 = OS

injection of
aflibercept
Baseline BCVA

BCVA prior to
receiving initial

Number

ODVABL = _.__
OSVABL = _.__

aflibercept
treatment for the
study eye

Snellen BCVA will be
converted to ETDRS logMAR
equivalent
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
Follow-Up

BCVA associated

BCVA

with each

Number

ODVA1 = _.__
OR

injection of

OSVA1 = _.__

aflibercept
Snellen BCVA will be
converted to ETDRS logMAR
equivalent
Baseline OCT

Central retinal

Number

thickness prior to

ODOCTBL = ___._ µm
OSOCTBL = ___._ µm

receiving initial
aflibercept
treatment
Follow-Up OCT

Central retinal
thickness
associated with
each injection of
aflibercept

Number

ODOCT1 = ___._ µm
OSOCT1 = ___._ µm
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Table 2 is a representation of the proposed general NAMD population data set.
Table 2
Example of Data Set for General NAMD Population
Variable

Definition

Coding of Variable

Patient ID

De-identified Patient

1001

Identification Number
Gender

Patient’s Gender

2

Race/Ethnicity

Patient’s reported race or

1

ethnicity
Age

Age in years calculated from
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the date of birth compared to
the date of the dataset
Iris Color

Ocular Comorbidities

The predominant color of the

ODIris = 2

iris in each eye

OSIris = 2

Does the patient have any of

1

the following ocular

4

comorbidities? (check all that
apply)
(table continues)
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Variable

Definition

Coding of Variable

Systemic

Does the patient have

1

Comorbidities

comorbidities associated with

8

any of the following body

9

systems? (check all that apply)

10

If yes, diagnosis associated

1 = Systemic Hypertension

Comorbidities

with body system

8 = Hysterectomy
9 = Chronic Obstructive
Pulmonary Disease
10 = Osteoarthritis

Smoking

Does the patient report a

2

history of smoking?
Alcohol Abuse

Does the patient report a

1

history of alcohol abuse
Genotype

Does the patient either of the

3

genotypes?
Eye Involved

Which eye(s) have a diagnosis

1

of NAMD
Diagnosis Date

Date the patient’s

ODDiag = 16 Nov 2012

ophthalmologist diagnosed
NAMD for each eye
(table continues)
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Variable

Definition

Coding of Variable

Length of Diagnosis

Calculated from the date of

ODLength = 2.72 years

diagnosis to the date of the
dataset
Study Eye

The eye which received the

1 = OD

first injection of aflibercept
Dates of Treatment

Aflibercept treatment dates for

ODTrt1 = 19 Nov 2012

each eye treated

ODTrt2 = 24 Dec 2012
ODTrt3 = 21 Jan 2013
ODTrt4 = 18 Feb 2013
ODTrt5 = 22 Apr 2013
ODTrt6 = 22 Jul 2013
ODTrt7 = 21 Oct 2013

Baseline BCVA

BCVA prior to receiving

ODVABL = 1.00

initial aflibercept treatment for
each eye treated
(table continues)
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Variable

Definition

Coding of Variable

Follow-Up BCVA

BCVA associated with each

ODVA1 = 0.98

injection of aflibercept

ODVA2 = 0.72
ODVA3 = 0.60
ODVA4 = 0.56
ODVA5 = 0.50
ODVA6 = 0.50
ODVA7 = 0.54

Baseline OCT

Central retinal thickness prior

ODOCTBL = 608

to receiving initial aflibercept
treatment
Follow-Up OCT

Central retinal thickness

ODOCT1 = 606

associated with each injection

ODOCT2 = 580

of aflibercept

ODOCT3 = 560
ODOCT4 = 500
ODOCT5 = 460
ODOCT6 = 445
ODOCT7 = 450

The patient data noted in Table 2 represents a 65-year-old, Caucasian, female, with blue
irides diagnosed with NAMD in the right eye (OD) on November. 16, 2008 (2.72 years
prior to data collection). The patient was also diagnosed with ocular conditions of
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cataract and glaucoma and systemic conditions of hypertension, hysterectomy, chronic
obstructive pulmonary disease, and osteoarthritis. The patient received seven treatments
OD (i.e., the study eye) with aflibercept between the dates of November. 19, 2012 and
October 21, 2013, with baseline BCVA of 1.00 logMAR, which improved to 0.54
logMAR by the final treatment and baseline central retinal thickness of 608 µm, which
improved to 450 µm by the final treatment.
Data Analysis Plan
The research questions for this study were:
Research Question 1: Were there significant differences between selected health
characteristics of populations of NAMD patients treated with aflibercept in three
private, retinal practices in geographically disperse population centers in the
United States? Health characteristic variables included: age, gender, number of
ocular comorbidities, number of systemic comorbidities, number of days between
NAMD diagnosis and first treatment with aflibercept in the study eye, baseline
BCVA, baseline OCT.
H01: µ1=µ2
There were no differences in proportions between selected health
characteristics of populations of NAMD patients treated with aflibercept
in three private, retinal practices in geographically disperse population
centers in the United States.
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Ha1: µ1≠µ2
There were differences in proportions between selected health
characteristics of populations of NAMD patients treated with aflibercept
in three private, retinal practices in geographically disperse population
centers in the United States.
My analysis for this research question included several different comparisons.
The categorical variable of gender was compared using the incidence of males and
females at each retinal practice using a two-tailed analysis with a = 0.05. I used a c2 test
of homogeneity to compare the variable incidence in each of the three retinal practices to
determine if differences in gender existed between the practices. The continuous
variables of age, number of ocular comorbidities, number of systemic comorbidities,
number of days between NAMD diagnosis and first treatment with aflibercept in the
study eye, baseline BCVA, and baseline OCT were compared using mean values for each
variable for each eye treated using a two-tailed analysis with a = 0.05. I used a one-way
ANOVA to compare the mean values of each variable in each of the three retinal
practices to determine differences exist between the practices.
Research Question 2: Were there significant differences between aflibercept
treatment regimens used to treat NAMD patient in three private, retinal practices
in geographically disperse population centers in the United States? Treatment
regimen variables included: average number of aflibercept treatments injections
received during one year from initial aflibercept treatment and average number of
days between aflibercept treatments.
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H02: µ1=µ2
There were no differences in the aflibercept treatment regimens used to
treat populations of NAMD among patients at three private, retinal
practices in geographically disperse population centers in the United
States.
Ha2: µ1≠µ2
There were differences in aflibercept treatment regimens used to treat
populations of NAMD among patients at three private, retinal practices in
geographically disperse population centers in the United States.
My analysis for this research question was a comparison of the two continuous
variables. This was accomplished using mean values for each variable for the study eye
treated using a two-tailed analysis with a = 0.05. I used a one-way ANOVA to compare
the mean values of each variable in each of the three retinal practices to determine
differences exist between the practices.
Research Question 3: Were there significant differences between aflibercept
treatment outcomes reported for NAMD patients in the three private, retinal
practices in geographically disperse population centers in the United States?
Treatment outcome variables included: average change from baseline in BCVA
and average change from baseline in OCT.
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H03: µ1=µ2
There were no differences between aflibercept treatment outcomes
reported for NAMD patients in three private, retinal practices in
geographically disperse population centers in the United States.
Ha3: µ1≠µ2
There were differences between aflibercept treatment outcomes reported
for NAMD patients in three private, retinal practices in geographically
disperse population centers in the United States.
My analysis for this research question was a comparison of the two continuous
variables. This was accomplished using mean values for each variable for the study eye
treated using a two-tailed analysis with a = 0.05. I used a one-way ANOVA to compare
the mean values of each variable in each of the three retinal practices to determine
differences exist between the practices.
Research Question 4: What associations existed between selected health
characteristics and aflibercept treatment regimens used to treat NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H04: ßĸ=0
There were no associations between selected health characteristics and
aflibercept treatment regimens used to treat NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
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Ha4: ßĸ≠0
There were associations between selected health characteristics and
aflibercept treatment regimens used to treat NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
My analysis for this research question included the use of comparisons and
correlations. I compared the categorical variable of gender using the incidence of males
and females compared to each of the treatment regimen variables at each retinal practice
using a two-tailed analysis with a = 0.05. Point-biserial correlation was used to
determine if associations existed between gender and treatment regimens. The continuous
variables of age, number of ocular comorbidities, number of systemic comorbidities,
number of days between NAMD diagnosis and first treatment with aflibercept in the
study eye, baseline BCVA, and baseline OCT were compared using mean values for each
variable for each eye treated using a two-tailed analysis with a = 0.05. I also used
Spearman’s correlation to determine if associations existed between the selected health
characteristics and treatment regimens.
Research Question 5: What associations existed between selected health
characteristics and aflibercept treatment outcomes reported for NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
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H05: ßĸ=0
There were no associations between selected health characteristics and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Ha5: ßĸ≠0
There were associations between selected health characteristics and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
I analyzed data for this research question in the following ways. The categorical
variable of gender was compared using the incidence of males and females compared to
each of the treatment regimen variables at each retinal practice using a two-tailed analysis
with a = 0.05. I used a point-biserial correlation to determine if associations existed
between gender and treatment outcomes. The continuous variables of age, number of
ocular comorbidities, number of systemic comorbidities, number of months since NAMD
diagnosis, baseline BCVA, and baseline OCT were compared using mean values for each
variable for each eye treated using a two-tailed analysis with a = 0.05. I used
Spearman’s correlation to determine if associations existed between the selected health
characteristics and treatment outcomes.
Research Question 6: What association existed between aflibercept treatment
regimens used and aflibercept treatment outcomes reported for NAMD patients in
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three private, retinal practices in geographically disperse population centers in the
United States?
H06: ßĸ=0
There were no associations between aflibercept treatment regimens used
and aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Ha6: ßĸ≠0
There were associations between aflibercept treatment regimens used and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
My analysis for this research question was a comparison of the two continuous
treatment regimen variables and the two continuous treatment outcomes variables. This
was accomplished using mean values for each variable for the study eye treated using a
two-tailed analysis with a = 0.05. I used Spearman’s correlation to determine if
associations existed between the selected health characteristics and the treatment
outcomes.
Analyses were conducted using IBM SPSS Statistics 23. Data were imported
from site EMR files and entered directly into the final SPSS database. The various
independent variables were classified into three groups based on the ophthalmic practice
from which the data were obtained (i.e., CA, KY, and OH). Data were assessed for
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outliers, normality, missing data, multicollinearity, and homogeneity of variance. Means
and standard deviations were reported for each variable from the secondary analysis of
the NAMD populations. Results of the ANOVA analyses were reported as F-statistic
with the associated between groups degrees of freedom followed by the within groups
degrees of freedom and the p-value. Results of the Spearman’s correlation were reported
as the correlation coefficient, rs, with the number of degrees of freedom followed by the
p-value.
Threats to Validity
Threats to validity include issues that jeopardize the ability of a researcher to
draw thorough and appropriate conclusions based on the data collected (FrankfortNachmias & Nachmias, 2007). Internal validity refers to the way in which studies are
designed and the manner in which data are collected (Frankfort-Nachmias & Nachmias,
2007). For this study, threats to internal validity occurred with respect to the general
NAMD population selection. This study was not randomized; therefore, it was necessary
identify patients based on diagnosis, treatment, and outcome measure availability in the
EMR systems of the participating sites. External validity deals with how well the results
of the study can be translated to a larger population (Frankfort-Nachmias & Nachmias,
2007). Generalizability from this study to other therapeutic interventions in NAMD and
in ophthalmology should be robust but may be questionable for other medical conditions.
Statistical conclusion validity was based on several issues pertaining to detecting errors
due to the analysis and/or data being analyzed. This study was initially designed to have
95% power to detect a Type 1 error. As well, the assumptions associated with analysis
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by ANOVA were tested to make certain that the inferences made, based on the analysis
of these data, were appropriate. As data were collected it became apparent that the
required number of patients (i.e., 252) to support the 95% power computation were not
available at the retinal practices identified. A total of 199 patients were identified, which
lowered the power of the study to detect a Type 1 error to 90%.
Ethical Procedures
All data collected in this study were de-identified prior to analysis as suggested by
the HIPAA. Data use agreements and letters of cooperation were completed with each of
the three retinal practice physicians in order to gain access to the EMR data for patients at
each office (Appendices A–C). As well, all applicable laws regarding privacy and
confidentiality were followed. This study was submitted to the Walden University
Institutional Review Board (IRB) for approval (IRB Approval Number 01-20-160246251) to ascertain whether the study complied with the ethical standards of the
university and U.S. federal regulations. Data were housed on a password-protected
computer with limited access by me only. Data will be destroyed 5 years after
completing the study.
Summary
This study was a retrospective, contrasted-groups, cross-sectional study design
wherein the categorical groups of three NAMD patient populations were contrasted with
respect to selected health characteristics, treatment regimens, and treatment outcomes.
The study was focused on the research question of whether disparities existed between
the three geographically disperse NAMD patient populations. NAMD patient population
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data were collected from three retina specialists located around the United States.
Secondary data analyses were performed on variables from this data collection to
determine the means and standard deviations in the general NAMD patient population.
One-way ANOVA and c2 analyses were performed to determine whether there were
differences between each of the retina practices with respect to selected health
characteristics, aflibercept treatment regimens, and aflibercept treatment outcomes.
Spearman’s correlation and point-biserial correlation were performed to determine
whether associations existed between selected health characteristics, aflibercept treatment
regimens, and aflibercept treatment outcomes. I will document the results of these
analyses in Chapter 4, and Chapter 5 will be used to elaborate how the results from this
study relate to other previously published literature.
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Chapter 4: Research Method
Introduction
The purpose of this study was to evaluate whether significant differences existed
regarding selected health characteristics, treatment regimens, and treatment outcomes for
patients with NAMD treated with aflibercept from three private, retinal practices in
geographically disperse population centers in the United States. The research questions
and hypotheses that guided this study were:
Research Question 1: Were there significant differences between selected health
characteristics of populations of NAMD patients treated with aflibercept in three
private, retinal practices in geographically disperse population centers in the
United States? Health characteristic variables included: age, gender, number of
ocular comorbidities, number of systemic comorbidities, number of days between
NAMD diagnosis and first treatment with aflibercept in the study eye, baseline
BCVA, and baseline OCT.
H01: µ1=µ2
There were no differences in proportions between selected health
characteristics of populations of NAMD patients treated with aflibercept
in three private, retinal practices in geographically disperse population
centers in the United States.
Ha1: µ1≠µ2
There were differences in proportions between selected health
characteristics of populations of NAMD patients treated with aflibercept
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in three private, retinal practices in geographically disperse population
centers in the United States.
Research Question 2: Were there significant differences between aflibercept
treatment regimens used to treat NAMD patient in three private, retinal practices
in geographically disperse population centers in the United States? Treatment
regimen variables included: average number of aflibercept treatments injections
received during one year from initial aflibercept treatment and average number of
days between aflibercept treatments.
H02: µ1=µ2
There were no differences in the aflibercept treatment regimens used to
treat populations of NAMD among patients at three private, retinal
practices in geographically disperse population centers in the United
States.
Ha2: µ1≠µ2
There were differences in aflibercept treatment regimens used to treat
populations of NAMD among patients at three private, retinal practices in
geographically disperse population centers in the United States.
Research Question 3: Were there significant differences between aflibercept
treatment outcomes reported for NAMD patients in the three private, retinal
practices in geographically disperse population centers in the United States?
Treatment outcome variables included: average change from baseline in BCVA
and average change from baseline in OCT.
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H03: µ1=µ2
There were no differences between aflibercept treatment outcomes
reported for NAMD patients in three private, retinal practices in
geographically disperse population centers in the United States.
Ha3: µ1≠µ2
There were differences between aflibercept treatment outcomes reported
for NAMD patients in three private, retinal practices in geographically
disperse population centers in the United States.
Research Question 4: What associations existed between selected health
characteristics and aflibercept treatment regimens used to treat NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H04: ßĸ=0
There were no associations between selected health characteristics and
aflibercept treatment regimens used to treat NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Ha4: ßĸ≠0
There were associations between selected health characteristics and
aflibercept treatment regimens used to treat NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
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Research Question 5: What associations existed between selected health
characteristics and aflibercept treatment outcomes reported for NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H05: ßĸ=0
There were no associations between selected health characteristics and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Ha5: ßĸ≠0
There were associations between selected health characteristics and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
Research Question 6: What association existed between aflibercept treatment
regimens used and aflibercept treatment outcomes reported for NAMD patients in
three private, retinal practices in geographically disperse population centers in the
United States?
H06: ßĸ=0
There were no associations between aflibercept treatment regimens used
and aflibercept treatment outcomes reported for NAMD patients in three
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private, retinal practices in geographically disperse population centers in
the United States.
Ha6: ßĸ≠0
There were associations between aflibercept treatment regimens used and
aflibercept treatment outcomes reported for NAMD patients in three
private, retinal practices in geographically disperse population centers in
the United States.
The research questions for this study were designed to evaluate potential
differences and associations between selected health characteristics, treatment regimens,
and treatment outcomes. This design was necessary to address the gap in the literature
related to aflibercept. Specifically, this study was designed to determine how aflibercept
treatment for NAMD compared in populations with characteristics different from or
treated in a manner that differed from the clinical trial populations.
In Chapter 4, I will present data collection methods along with any discrepancies
from the plan presented in Chapter 3. I will also provide descriptive statistics pertaining
to the three retinal practice populations. Statistical analyses as proposed in Chapter 3 will
be presented and explained relative to the research question posed.
Data Collection
I obtained the data for this study from EMR data from three retinal practices
located in Hollywood, CA, Paducah, KY, and Cuyahoga Falls, OH from March 22, 2016
through October 26, 2016. Permission to use these data was granted by both the Walden
University IRB and by each of the physicians in the retinal practices chosen. As this was
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a retrospective study wherein subject information was de-identified, it was not necessary
to obtain informed consent to review the patients’ EMR information. The original plan
was to collect information on race/ethnicity, iris color, and NAMD genotype as a part of
the selected health characteristics; however, these characteristics were not reported in the
medical records of the selected retina specialists. As well, the age variable was originally
going to be calculated as the date of the database compared to the birthdate. This
calculation was determined to be faulty in that it could result in ages beyond which the
subject had lived. Instead, the age was calculated comparing the birthdate to the first day
of aflibercept treatment. Other changes in data collection or data naming conventions are
defined in Table 3 and included: (a) the eye involved field was deleted as it was deemed
to be unnecessary in that only study eye (SE) data were analyzed; (b) only data for the
selected SEs were collected resulting in the renaming of several fields that had originally
been specific to either OD or OS; (c) field renaming resulted in the following:
DiagDate_SE, DiagTrtTime, Aflib1_SE with all subsequent treatment dates coded
sequentially from Aflib1_SE, LogMAR1_SE with all subsequent VAs coded sequentially
from LogMAR1_SE, OCT1_SE with all subsequent OCTs coded sequentially from
OCT1_SE ; (d) a field of OCTDate1_SE and subsequent additional OCT dates were
added to the data capture since the OCT date was not always the same as the treatment
date; (e) additional ocular comorbidities and all systemic comorbidities were collected as
verbatim terms and were not coded into body system categories as it was not deemed
necessary; and (f) the data captured with regard to timing of diagnosis were compared to
the date of first aflibercept treatment rather than the date of the database, as researchers
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have stated that the improvement seen is more significant if the neovascularization is
caught in its early phase (Lim et al., 2012). The final database structure was as follows
in Table 3.
Table 3
Actual Variables and Coding for General NAMD Population
Variable

Definition

Nature of

Coding of Variable

Variable
Patient_No

De-identified Patient

Text

Identification Number

Site 1 (CA) =
1001 – 1999
Site 2 (KY) =
2001 – 2999
Site 3 (OH) =
3001 – 4999

DB_Date
Gender

Date of the final database
Patient’s Gender

Date

DD MMM YYYY

Dichotomous 1 = Male
2 = Female

Birthdate
Age

Patient’s Date of Birth
Age in years at the time the first

Date
Numeric

DD MMM YYYY
__.__ years

Aflibercept treatment was given
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
SmkHx

Does the patient report a history

Dichotomous 1 = No

of smoking?
AlcAbuse

Does the patient report a history

2 = Yes
Dichotomous 1 = No

of alcohol abuse?
Total_OMH

The total number of ocular

2 = Yes
Numeric

comorbidities

Number derived
from summation of
Ocular
Comorbidities and
OcuSpec1 through
OcuSpec5

Ocular

Does the patient have any of the

Numeric

1 = No

Comorbidities

following ocular comorbidities?

2 = Yes

CAT = Cataract

3 = Unknown

CMV = Cytomegalovirus
Retinitis
DME = Diabetic Macular Edema
GLAUC = Glaucoma
KCON = Keratoconus
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
PVD = Posterior Vitreous
Detachment RVO = Retinal Vein
Occlusion
UV = Uveitis
OTHER = Other (Specify)
OcuSpec1
through

Specification of other Ocular

Text

Comorbidities

Free text
description of other

OcuSpec5

ocular
comorbidities not
specified in the
supplied list.

Total_SMH

The total number of systemic
comorbidities

Numeric

Number derived
from summation of
SysComor1
through
SysComor20
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
SysComor1
through

Specification of Systemic

Text

Comorbidities

Free text
description of other

SysComor20

systemic
comorbidities.

Study Eye

The study eye is identified as that

Categorical

eye which received treatment

1 = OD
2 = OS

with Aflibercept first
DiagDate_SE

Date the patient’s

Date

DD MON YYYY

ophthalmologist diagnosed
NAMD for the study eye
DiagTrtTime

Number of days from diagnosis

Numeric

__.__ days

of NAMD to treatment with
aflibercept as calculated from the
date of diagnosis to the date of
the first treatment with
Aflibercept
AflibTrt1_SE
through

Aflibercept treatment dates for

Date

DD MON YYYY

the study eye

AflibTrt13_SE
(table continues)
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Variable

Definition

Nature of

Coding of Variable

Variable
LogMAR1_SE
through

BCVA reported as ETDRS

Numeric

_.__

logMAR values for each

LogMAR13_SE treatment date
OCTDate1_SE
through

OCT evaluation dates for the

Date

DD MON YYYY

study eye

OCTDate13_SE
OCT1_SE
through
OCT13_SE

OCT central retinal thickness

Number

___._ µm

associated with each injection of
aflibercept

For this study, I collected data from physicians’ EMR databases from March 22,
2016 through October 26, 2016. It was necessary to travel to the physician’s office in
Hollywood, CA, to collect the required data for the project. Data from the Paducah, KY
and the Cuyahoga Falls, OH sites were made available online by the system administrator
for the practice. The patients identified as being appropriate for inclusion in this study
comprised 199 total patients from the three retinal practices. These 199 patients were
culled from a total of 1,501 potential patients which was a 13.3% catchment. My
selection of the patients was based on the following criteria:
•

Diagnosis of NAMD in at least one eye.

•

Treatment with aflibercept intravitreal injections after approval in 2011.
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•

At least one BCVA and OCT assessment within approximately 1-month
period prior to treatment with aflibercept.

•

At least three BCVA and OCT assessments during the approximately 1-year
period following treatment with aflibercept.

The first of these criteria was changed from the original plan to increase the potential
subject pool. The original criterion included a date restriction of between 2011 and 2014.
The date restriction was determined unnecessary since the criterion associated with use of
aflibercept resulted in a more effective culling of patients. Originally, it was proposed to
have collected 252 cases from the three retinal practices to achieve a 95% power to detect
a Type 1 error at a = 0.05. Based on the data available in the EMRs for these practices,
199 Patients were identified from the three retinal practices. Nonetheless, power to
detect a Type 1 error at an a = 0.05 was maintained at 90% with the 199 patients
included in the project.
There were 179 patients identified from the initial sampling of EMR data at the
retinal practice in Hollywood, CA. From the initial sampling at this practice, the final
number of patients included in the project database was 44. This represents 24.6% of the
total patients from the CA site and 22.1% of the total population. There were 178
patients from the initial sampling of EMR data at the retinal practice in Paducah, KY.
From the initial sampling at this practice, the final number of patients included was 101.
This represents 56.7% of the total patients from the KY site and 50.8% of the total
population. There were 1,144 patients from the initial sampling of EMR data at the
retinal practice in Cuyahoga Falls, OH. From the initial sampling at this practice, the
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final number of patients included in the project database was 54. This represents 4.7% of
the total patients from the OH site and 27.1% of the total population.
Results
General Population Demographics
Overall demographic descriptive statistics were performed on the final data
sample collected. The data from all three retinal practices combined included 78 males
(39.2%) and 121 females (60.8%). This represents a population that is slightly skewed (0.446) toward women. This type of skewness is appropriate based on findings that
NAMD is more prevalent in women (NEI, 2014). The mean age of the population at the
time of the subject’s first treatment with aflibercept was 78.8 ± 8.542 years. This is
skewed towards older age (-0.410), which is to be expected due to the age-related nature
of NAMD (NEI, 2014). The minimum age reported was 45 years and the maximum age
was 95 years. As has been mentioned previously, AMD is the most common cause of
visual impairment after the age of 55 with the risk reaching 11.73% by the time
individuals approach their eighth decade (Coleman et al., 2008; NEI, 2014).
The smoking history and alcohol abuse findings were somewhat unexpected as
having a history of smoking or alcohol abuse have been reported as being associated with
incidence of NAMD (The Foundation of the American Academy of Ophthalmology,
2015). In the population studied, 137 (68.8%) patients reported no smoking history, 47
(23.6%) patients reported having a history of smoking, and 15 (7.5%) patients did not
report their smoking history; therefore, they were classified as unknown. The findings
for alcohol abuse were much less robust than had been anticipated with 174 (87%)
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patients reporting no history of alcohol abuse, two (1%) patients reporting a history of
alcohol abuse, and 24 (12%) patients not reporting their alcohol abuse history. The
patients with no report of alcohol abuse were also coded as unknown. Since the patient
reports of smoking and alcohol abuse history did not seem reliable, no further evaluations
were performed on these variables.
Patients in the population under study had an average of 3.00 ± 1.12 ocular
comorbidities. The minimum number of ocular comorbidities was one, and the
maximum number was seven. All patients were reported to have a diagnosis of AMD
(ICD-9 code of 362.52). The most common comorbidity reported other than AMD was
cataract with 174 (87.4%) patients being diagnosed with cataract in at least one eye.
Other ocular comorbidities reported were glaucoma (n = 29, 14.6%), posterior vitreous
detachment (n = 20, 10.1%), retinal vein occlusion (n = 8, 4.0%), and uveitis (n = 1,
0.5%). Other ocular comorbidities that were not specified in the original listing were
reported by 111 patients (55.8%). The patients in this population reported having 5.65 ±
3.15 systemic comorbidities. The minimum number of systemic comorbidities reported
was zero and the maximum number was 20. The most common systemic comorbidities
(incidence > 15%) are listed in Table 4.
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Table 4
Systemic Comorbidities Reported at >15% Incidence
Comorbidity

Frequency and Percentage of Systemic Comorbidities
(N = 199)

Hypertension

132

66%

Arthritis

87

44%

Cancer

58

29%

Hyperlipidemia

50

25%

Hypothyroidism

38

19%

Depression

35

18%

Diabetes

34

17%

Cardiovascular Disease

32

16%

Note. N = Total number of patients.

Regarding variables specific to NAMD for the overall study population, time
from diagnosis to first aflibercept treatment, baseline BCVA, and baseline OCT were
evaluated. The mean between diagnosis with NAMD and the first treatment with
aflibercept was 323.6 ± 410.6 days. The large degree of variation in this variable was
notable and was most likely due to NAMD diagnoses that were well before aflibercept
was approved and marketed in 2011. Mean baseline VA for the general population
reported in ETDRS logMAR was 0.53 ± 0.39 and mean baseline OCT was 333.26 ±
110.79 µm. The mean number of aflibercept treatments given during the approximately
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1-year period following the first aflibercept treatment was 7.24 ± 1.861 and the mean
number of days between treatments was 63.4858 ± 33.02454. Mean change from
baseline BCVA was -0.0073 ± 0.30373 and mean change from baseline OCT was 43.8750 ± 96.27885.
Statistical Analyses
Research Question 1.
A one-way ANOVA was conducted to determine if age at the time of first
treatment with aflibercept (AGE) was different between the three physician groups. AGE
had no significant outliers and was normally distributed across the population and
between the physician groups, as assessed by visual inspection of a normal Q-Q Plot.
There was homogeneity of variances as assessed by Levene’s test of homogeneity of
variance (p = 0.468). AGE data are presented as mean ± standard deviation in Table 5.
Table 5
AGE (years) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

79.98

9.444

KY

101

77.88

8.222

OH

54

79.50

8.332

Total

199

78.78

8.542

AGE was not statistically significantly different between the three physician practices,
F(2,196) = 1.185, p = 0.308. The null hypothesis was not rejected.
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A c2 test of homogeneity was conducted to determine if GENDER was different
between the three physician groups. Gender data are presented as frequencies in Table 6.
Table 6
GENDER Frequencies by Physician Group and Total
Physician Group

Number of Patients

Male

Female

CA

44

19 (43.2%)

25 (56.8%)

KY

101

42 (41.6%)

59 (58.4%)

OH

54

17 (31.5%)

37 (68.5%)

Total

199

78 (39.2%)

121 (60.8%)

GENDER was not statistically significantly different between the three physician groups,
c2 = 1.1883, p = 0.390. The null hypothesis was not rejected.
A one-way ANOVA was conducted to determine if the average number of ocular
comorbidities (OCULAR) per patient was different between the three physician groups.
OCULAR had no significant outliers and was normally distributed across the population
and between the physician groups, as assessed by visual inspection of a normal Q-Q Plot.
There was homogeneity of variances as assessed by Levene’s test of homogeneity of
variance (p = 0.470). OCULAR data are presented as mean ± standard deviation in Table
7.
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Table 7
OCULAR Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

3.23

1.236

KY

101

2.83

1.059

OH

54

3.13

1.082

Total

199

3.00

1.115

OCULAR was not statistically significantly different between the three physician
practices, F(2,196) = 2.467, p = 0.087. The null hypothesis was not rejected.
A one-way Welch ANOVA was conducted to determine if the average number of
systemic comorbidities (SYSTEMIC) per patient was different between the three
physician groups. SYSTEMIC had no significant outliers and was normally distributed
across the population and between the physician groups, as assessed by visual inspection
of a normal Q-Q Plot. There was heterogeneity of variances as assessed by Levene’s test
of homogeneity of variance (p = 0.042). SYSTEMIC data are presented as mean ±
standard deviation in Table 8.
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Table 8
SYSTEMIC Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

3.23

1.236

KY

101

2.83

1.059

OH

54

3.13

1.082

Total

199

5.65

3.160

SYSTEMIC was statistically significantly different between different physician groups,
Welch’s F(2,196) = 4.106, p = 0.018. Games-Howell testing in the variable, SYSTEMIC,
revealed a statistically significant difference between KY and OH with a mean difference
in the number of systemic medical history items reported of 1.479 (95% CI [0.40,2.56, p
= 0.004]). The null hypothesis was rejected for SYSTEMIC between KY and OH. For
all other relationships, the null hypothesis was not rejected.
A one-way Welch ANOVA was conducted to determine if the numbers of days
between the diagnosis of NAMD and the first treatment with aflibercept (DIAGTRT) was
different between the three physician groups. DIAGTRT had no significant outliers and
was normally distributed across the population and between the physician groups, as
assessed by visual inspection of a normal Q-Q Plot. There was heterogeneity of
variances as assessed by Levene’s test of homogeneity of variance (p < 0.001).
DIAGTRT data are presented as mean ± standard deviation in Table 9.
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Table 9
DIAGTRT (days) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

484.25

594.997

KY

101

338.01

337.864

OH

54

164.96

282.467

Total

199

323.39

410.607

DIAGTRT was statistically significantly different between different physician
groups, Welch’s F(2,196) = 7.986, p < 0.001. Games-Howell testing in the variable,
DIAGTRT, revealed a statistically significant difference in DIAGTRT between CA and
OH with mean difference reported as 319.287 (95% CI [84.62,553.95, p = 0.005]), and
the mean difference between KY and OH reported as 173.047 (95% CI [51.93,294.16, p
= 0.003]). The null hypothesis was rejected for DIAGTRT between CA and OH as well
as between KY and OH. For all other relationships, the null hypothesis was not rejected.
A one-way ANOVA was conducted to determine if the Baseline VA (BLVA) was
different between the different physician groups. BLVA had no significant outliers and
was normally distributed across the population and between the physician groups, as
assessed by visual inspection of a normal Q-Q Plot. There was homogeneity of variances
as assessed by Levene’s test of homogeneity of variance (p = 0.106). BLVA data are
presented as mean ± standard deviation in Table 10.
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Table 10
BLVA (logMAR) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

0.4377

0.32155

KY

101

0.6051

0.43855

OH

54

0.4807

0.33678

Total

199

0.5344

0.39416

BLVA was statistically significantly different between the three physician practices,
F(2,196) = 3.539, p = 0.031. Tukey Post Hoc analysis revealed the mean increase in
BLVA from KY to CA (0.16742, 95% CI [0.0014, 0.3335, p = 0.048]) was statistically
significant. The null hypothesis was rejected for BLVA between KY and CA. For all
other relationships, the null hypothesis was not rejected.
A one-way ANOVA was conducted to determine if the Baseline OCT (BLOCT)
was different between the different physician groups. BLOCT had no significant outliers
and was normally distributed across the population and between the physician groups, as
assessed by visual inspection of a normal Q-Q Plot. There was homogeneity of variances
as assessed by Levene’s test of homogeneity of variance (p = 0.224). BLOCT data are
presented as mean ± standard deviation in Table 11.
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Table 11
BLOCT (µM) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

294.23

104.688

KY

101

364.90

114.007

OH

54

305.89

92.238

Total

199

333.26

110.795

BLOCT was statistically significantly different between the three physician practices,
F(2,196) = 9.201, p < 0.001. Tukey Post Hoc analysis revealed the mean increase in
BLOCT from KY to CA (70.674, 95% CI [25.25, 116.09, p = 0.001]) was statistically
significant. The null hypothesis was rejected for BLOCT between KY and CA. For all
other relationships, the null hypothesis was not rejected.
Research Question 2.
A one-way ANOVA was conducted to determine if the average total number of
aflibercept treatments given in the approximately 1-year period after the first aflibercept
(NUMTRT) was different between the different physician groups. NUMTRT had no
significant outliers and was normally distributed across the population and between the
physician groups, as assessed by visual inspection of a normal Q-Q Plot. There was
homogeneity of variances as assessed by Levene’s test of homogeneity of variance (p =
0.355). NUMTRT data are presented as mean ± standard deviation in Table 12.
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Table 12
NUMTRT Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

8.55

1.956

KY

101

7.08

1.647

OH

54

6.46

1.634

Total

199

7.24

1.861

NUMTRT was statistically significantly different between the three physician practices,
F(2,196) = 18.759, p < 0.001. Tukey Post Hoc analysis revealed the mean increase in
NUMTRT from CA to KY (1.466, 95% CI [0.74, 2.20]) was statistically significant (p <
0.001), and the mean increase in NUMTRT from CA to OH (2.082, 95% CI [1.26, 2.90])
was statistically significant (p < 0.001). The null hypothesis was rejected for NUMTRT
between CA and KY as well as for CA and OH. For all other relationships, the null
hypothesis was not rejected.
A one-way ANOVA was conducted to determine if the average number of days
between aflibercept treatments (NUMDAY) was different between the different
physician groups. NUMDAY had no significant outliers and was normally distributed
across the population and between the physician groups, as assessed by visual inspection
of a normal Q-Q Plot. There was homogeneity of variances as assessed by Levene’s test
of homogeneity of variance (p = 0.196). NUMTRT data are presented as mean ±
standard deviation in Table 13.
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Table 13
NUMDAY (days) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

45.9056

16.79308

KY

101

55.8789

20.76874

OH

54

58.1092

21.49334

Total

199

54.2790

20.58245

NUMDAY was statistically significantly different between the three physician practices,
F(2,196) = 5.081, p = 0.007. Tukey Post Hoc analysis revealed the mean increase in
NUMDAY from KY to CA (0.97327, 95% CI [1.3686,18.5780,] p = 0.018) and the mean
increase in NUMDAY from OH to CA (12.20354, 95% CI [2.5290, 21.8780], p = 0.009).
The null hypothesis was rejected for NUMDAY between KY to CA as well as between
OH and CA. For all other relationships, the null hypothesis was not rejected.
Research Question 3.
A one-way ANOVA was conducted to determine if change from baseline VA
reported in the approximately one-year period following the first aflibercept treatment
(BCVA) was different between the different physician groups. BCVA had no significant
outliers and was normally distributed across the population and between the physician
groups, as assessed by visual inspection of a normal Q-Q Plot. There was homogeneity
of variances as assessed by Levene’s test of homogeneity of variance (p = 0.731). BCVA
data are presented as mean ± standard deviation in Table 14.
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Table 14
BCVA (logMAR) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

-0.0804

0.32370

KY

101

0.0113

0.30985

OH

54

0.0174

0.26973

Total

199

-0.0073

0.30373

BCVA was not statistically significantly different between the three physician practices,
F(2,196) = 1.654, p < 0.194. The null hypothesis was not rejected.
A one-way Welch ANOVA was conducted to determine change from baseline
OCT reported in the approximately one-year period following the first aflibercept
treatment (OCT) was different between the three physician groups. OCT had no
significant outliers and was normally distributed across the population and between the
physician groups, as assessed by visual inspection of a normal Q-Q Plot. There was
heterogeneity of variances as assessed by Levene’s test of homogeneity of variance (p =
0.042). OCT data are presented as mean ± standard deviation in Table 15.
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Table 15
OCT (µM) Mean and Standard Deviation by Physician Group and Total
Physician Group

Number of Patients

Mean

Standard Deviation

CA

44

-36.5779

93.35451

KY

101

-57.4915

110.93797

OH

54

-24.3527

59.59982

Total

199

-43.8750

96.27885

OCT was not statistically significantly different between different physician groups,
Welch’s F(2,196) = 2.276, p = 0.105. The null hypothesis was not rejected.
Research Question 4.
A Spearman’s rank-order correlation was conducted to assess the relationship
between AGE and NUMDAY. There was a monotonic relationship between AGE and
NUMDAY, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between AGE and NUMDAY, rs(199) = -0.066, p = 0.356. The
null hypothesis for association between AGE and NUMDAY was not rejected. Further, a
Spearman’s rank-order correlation was conducted to assess the relationship between AGE
and NUMTRT. There was a monotonic relationship between AGE and NUMTRT, as
assessed by visual inspection of a scatterplot. There was a statistically significant
positive correlation between AGE and NUMTRT, rs(199) = 0.151, p = 0.033; therefore,
the null hypothesis for association between AGE and NUMTRT was rejected.
A point-biserial correlation was conducted between GENDER and NUMDAY.
Assumption analyses of GENDER and NUMDAY showed (a) there were outliers, as
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assessed by boxplot; (b) score was not normally distributed, as assessed by ShapiroWilk's test (p < 0.05); but (c) there was homogeneity of variances, as assessed by
Levene's test for equality of variances. Although the assumptions were not all met, it was
determined that the point-biserial correlation would be performed to gain some insight
into whether an association might exist between GENDER and NUMDAY. There was
no statistically significant correlation between GENDER and NUMDAY, rpb(199) = 0.021, p = 0.773 The null hypothesis for association between GENDER and NUMDAY
was not rejected. As well, a point-biserial correlation was conducted between GENDER
and NUMTRT. Assumption analyses of GENDER and NUMTRT showed (a) there were
outliers, as assessed by boxplot; (b) score was not normally distributed, as assessed by
Shapiro-Wilk's test (p < 0.05); but (c) there was homogeneity of variances, as assessed by
Levene's test for equality of variances. Although the assumptions were not all met, it was
determined that the point-biserial correlation would be performed to gain some insight
into whether an association might exist between GENDER and NUMTRT. There was no
statistically significant correlation between GENDER and NUMTRT, rpb(199) = 0.036, p
= 0.618. The null hypothesis for association between GENDER and NUMTRT was not
rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between OCULAR and NUMDAY. There was a monotonic relationship between the
OCULAR and NUMDAY, as assessed by visual inspection of a scatterplot. There was
no statistically significant correlation between OCULAR and NUMDAY, rs(199) =
0.027, p = 0.705; therefore, the null hypothesis for association between OCULAR and
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NUMDAY was not rejected. Further, a Spearman’s rank-order correlation was
conducted to assess the relationship between OCULAR and NUMTRT. There was a
monotonic relationship between OCULAR and NUMTRT, as assessed by visual
inspection of a scatterplot. There was no statistically significant correlation between
OCULAR and NUMTRT, rs(199) = -0.007, p = 0.922; therefore, the null hypothesis for
association between OCULAR and NUMTRT was not rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between SYSTEMIC and NUMDAY. There was a monotonic relationship between
SYSTEMIC and NUMDAY, as assessed by visual inspection of a scatterplot. There was
a no statistically significant correlation between SYSTEMIC and NUMDAY, rs(199) = 0.046, p = 0.520; therefore, the null hypothesis for SYSTEMIC and NUMDAY was not
rejected. Further, a Spearman’s rank-order correlation was conducted to assess the
relationship between SYSTEMIC and NUMTRT. There was a monotonic relationship
between SYSTEMIC and NUMTRT, as assessed by visual inspection of a scatterplot.
There was no statistically significant correlation between SYSTEMIC and NUMTRT,
rs(199) = -0.107, p = 0.134; therefore, the null hypothesis for association between
SYSTEMIC and NUMTRT was not rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between DIAGTRT and NUMDAY. There was a monotonic relationship between
DIAGTRT and NUMDAY, as assessed by visual inspection of a scatterplot. There was a
statistically significant negative correlation between DIAGTRT and NUMDAY, rs(199)
= -0.220, p = 0.002; therefore, the null hypothesis for DIAGTRT and NUMDAY was
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rejected. Further, a Spearman’s rank-order correlation was conducted to assess the
relationship between DIAGTRT and NUMTRT. There was a monotonic relationship
between DIAGTRT and NUMTRT, as assessed by visual inspection of a scatterplot.
There was statistically significant positive correlation between DIAGTRT and
NUMTRT, rs(199) = 0.200, p = 0.005; therefore, the null hypothesis for association
between DIAGTRT and NUMTRT was rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between BLVA and NUMDAY. There was a monotonic relationship between BLVA
and NUMDAY, as assessed by visual inspection of a scatterplot. There was no
statistically significant correlation between BLVA and NUMDAY, rs(199) = 0.008, p =
0.911; therefore, the null hypothesis for BLVA and NUMDAY was not rejected. Further,
a Spearman’s rank-order correlation was conducted to assess the relationship between
BLVA and NUMTRT. There was a monotonic relationship between BLVA and
NUMTRT, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between BLVA and NUMTRT, rs(199) = -0.098, p = 0.169;
therefore, the null hypothesis for association between BLVA and NUMTRT was not
rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between BLOCT and NUMDAY. There was a monotonic relationship between BLOCT
and NUMDAY, as assessed by visual inspection of a scatterplot. There was a statistically
significant negative correlation between BLOCT and NUMDAY, rs(199) = -0.141, p =
0.047; therefore, the null hypothesis for BLOCT and NUMDAY was rejected. Further, a
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Spearman’s rank-order correlation was conducted to assess the relationship between
BLOCT and NUMTRT. There was a monotonic relationship between BLOCT and
NUMTRT, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between BLOCT and NUMTRT, rs(199) = 0.089, p = 0.210;
therefore, the null hypothesis for association between BLOCT and NUMTRT was not
rejected.
Research Question 5.
A Spearman’s rank-order correlation was conducted to assess the relationship
between AGE and BCVA. There was a monotonic between AGE and BCVA, as
assessed by visual inspection of a scatterplot. There was no statistically significant
correlation between AGE and BCVA, rs(199) = -0.055, p = 0.438. The null hypothesis
for association between AGE and BCVA was not rejected. Further, a Spearman’s rankorder correlation was conducted to assess the relationship between AGE and OCT. There
was a monotonic relationship between AGE and OCT, as assessed by visual inspection of
a scatterplot. There was no statistically significant correlation between AGE and OCT,
rs(199) = 0.000, p = 0.997; therefore, the null hypothesis for association between AGE
and OCT was not rejected.
A point-biserial correlation was conducted between GENDER and BCVA.
Assumption analyses of GENDER and BCVA showed (a) there were outliers, as assessed
by boxplot; (b) score was not normally distributed, as assessed by Shapiro-Wilk's test (p
< 0.05); but (c) there was homogeneity of variances, as assessed by Levene's test for
equality of variances. Although the assumptions were not all met, it was determined that
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the point-biserial correlation would be performed to gain some insight into whether an
association might exist between GENDER and BCVA. There was no statistically
significant correlation between GENDER and BCVA, rpb(199) = -0.008, p = 0.912. The
null hypothesis for association between GENDER and BCVA was not rejected. As well,
a point-biserial correlation was conducted between GENDER and OCT. Assumption
analyses of GENDER and OCT showed (a) there were outliers, as assessed by boxplot;
(b) score was not normally distributed, as assessed by Shapiro-Wilk's test (p < 0.05); but
(c) there was homogeneity of variances, as assessed by Levene's test for equality of
variances. Although the assumptions were not all met, it was determined that the pointbiserial correlation would be performed to gain some insight into whether an association
might exist between GENDER and OCT. There was no statistically significant
correlation between GENDER and OCT, rpb(199) = 0.059, p = 0.409. The null hypothesis
for association between GENDER and OCT was not rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between OCULAR and BCVA. There was a monotonic relationship between OCULAR
and BCVA, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between OCULAR and BCVA, rs(199) = 0.011, p = 0.881;
therefore, the null hypothesis for association between OCULAR and BCVA was not
rejected. Further, a Spearman’s rank-order correlation was conducted to assess the
relationship between OCULAR and OCT. There was a monotonic relationship between
OCULAR and OCT, as assessed by visual inspection of a scatterplot. There was no
statistically significant correlation between OCULAR and OCT, rs(199) = 0.042, p =

108
0.557; therefore, the null hypothesis for association between OCULAR and OCT was not
rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between SYSTEMIC and BCVA. There was a monotonic relationship between
SYSTEMIC and BCVA, as assessed by visual inspection of a scatterplot. There was no
statistically significant correlation between SYSTEMIC and BCVA, rs(199) = -0.102, p =
0.152; therefore, the null hypothesis for SYSTEMIC and BCVA was not rejected.
Further, a Spearman’s rank-order correlation was conducted to assess the relationship
between SYSTEMIC and OCT. There was a monotonic relationship between
SYSTEMIC and OCT, as assessed by visual inspection of a scatterplot. There was no
statistically significant correlation between SYSTEMIC and OCT, rs(199) = -0.051, p =
0.477; therefore, the null hypothesis for association between SYSTEMIC and OCT was
not rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between DIAGTRT and BCVA. There was a monotonic relationship between DIAGTRT
and BCVA, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between DIAGTRT and BCVA, rs(199) = 0.128, p = 0.071;
therefore, the null hypothesis for DIAGTRT and BCVA was not rejected. Further, a
Spearman’s rank-order correlation was conducted to assess the relationship between
DIAGTRT and OCT. There was a monotonic relationship between DIAGTRT and OCT,
as assessed by visual inspection of a scatterplot. There was statistically significant
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positive correlation between DIAGTRT and OCT, rs(199) = -0.044, p = 0.533; therefore,
the null hypothesis for association between DIAGTRT and OCT was not rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between BLVA and BCVA. There was a monotonic relationship between BLVA and
BCVA, as assessed by visual inspection of a scatterplot. There was a highly statistically
significant negative correlation between BLVA and BCVA, rs(199) = -0.308, p < 0.001;
therefore, the null hypothesis for BLVA and BCVA was rejected. Further, a Spearman’s
rank-order correlation was conducted to assess the relationship between BLVA and OCT.
There was a monotonic relationship between BLVA and OCT, as assessed by visual
inspection of a scatterplot. There was highly statistically significant negative correlation
between BLVA and OCT, rs(199) = -0.193, p = 0.006; therefore, the null hypothesis for
association between BLVA and OCT was rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between BLOCT and BCVA. There was a monotonic relationship between BLOCT and
BCVA, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between BLOCT and BCVA, rs(199) = -0.025, p = 0.726;
therefore, the null hypothesis for BLOCT and BCVA was not rejected. Further, a
Spearman’s rank-order correlation was conducted to assess the relationship between
BLOCT and OCT. There was a monotonic relationship between BLOCT and OCT, as
assessed by visual inspection of a scatterplot. There was a highly statistically significant
negative correlation between BLOCT and OCT, rs(199) = -0.721, p < 0.001; therefore,
the null hypothesis for association between BLOCT and OCT was rejected.

110
Research Question 6.
A Spearman’s rank-order correlation was conducted to assess the relationship
between NUMDAY and BCVA. There was a monotonic relationship between
NUMDAY and BCVA, as assessed by visual inspection of a scatterplot. There was no
statistically significant correlation between NUMDAY and BCVA, rs(199) = 0.103, p =
0.148; therefore, the null hypothesis for NUMDAY and BCVA was not rejected.
Further, a Spearman’s rank-order correlation was conducted to assess the relationship
between NUMDAY and OCT. There was a monotonic relationship between NUMDAY
and OCT, as assessed by visual inspection of a scatterplot. There was a highly
statistically significant negative correlation between NUMDAY and OCT, rs(199) =
0.197, p = 0.005; therefore, the null hypothesis for association between NUMDAY and
OCT was rejected.
A Spearman’s rank-order correlation was conducted to assess the relationship
between NUMTRT and BCVA. There was a monotonic relationship between NUMTRT
and BCVA, as assessed by visual inspection of a scatterplot. There was no statistically
significant correlation between NUMTRT and BCVA, rs(199) = -0.032, p = 0.656;
therefore, the null hypothesis for NUMTRT and BCVA was not rejected. Further, a
Spearman’s rank-order correlation was conducted to assess the relationship between
NUMTRT and OCT. There was a monotonic relationship between NUMTRT and OCT,
as assessed by visual inspection of a scatterplot. There was a highly statistically
significant negative correlation between NUMTRT and OCT, rs(199) = -0.191, p = 0.007;
therefore, the null hypothesis for association between NUMTRT and OCT was rejected.
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Summary
In this study, I examined whether significant differences existed with regard to
selected health characteristics, treatment regimens, and treatment outcomes for patients
with NAMD treated with aflibercept from three private, retinal practices in
geographically disperse population centers in the United States. Potential associations
between selected health characteristics, treatment regimens, and treatment outcomes were
evaluated to address the gap in the literature related to aflibercept. Finally, I evaluated
how aflibercept treatment for NAMD performed in populations with characteristics
different from or treated in a manner that differed from the clinical trial populations.
There were differences between the three different retinal practices regarding the
number of systemic medical history items reported for KY/OH. Additionally, the time
from the initial diagnosis with NAMD and the first treatment with aflibercept differed
between CA/OH and KY/OH. BLVA and BLOCT differences were noted between
KY/CA. The number of days between aflibercept treatments differed between OH/CA,
and the total number of aflibercept treatments differed between CA/KY and CA/OH.
Associations were noted in age and number of aflibercept treatments, time from diagnosis
to first aflibercept treatment and number of days between aflibercept treatments, time
from diagnosis to first aflibercept treatment and total number of aflibercept treatments,
BLVA and BCVA, BLVA and OCT, and BLOCT and OCT.
In Chapter 5, I will review the results provided in Chapter 4 and how they related
to current literature and the appropriateness of extrapolating the results to the larger
population of patients being treated with aflibercept. In Chapter 5, I will also provide
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insight into the limitations of the study and any recommendations for future research in
this field. Finally, conclusions pertaining to this study will be detailed.
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Chapter 5: Discussions, Conclusions, and Recommendations
Introduction
This study was a retrospective, contrasted group, cross-sectional, secondary
analysis of data. The purpose of this study was to evaluate selected health characteristics,
treatment regimens, and treatment outcomes for patients with NAMD treated with
aflibercept from three private, retinal practices in geographically disperse population
centers in the United States. The aim of the study was to determine whether differences
or associations existed in these populations.
The key findings from this study were that NAMD patients included from the
three geographically disperse retinal practices were similar with respect to the some of
the more general selected health characteristics (i.e., age, gender, and ocular
comorbidities). There were significant differences between NAMD patients in these
physician practices with regard to some of the more specific selected health
characteristics (i.e., systemic comorbidities, time from initial diagnosis to first treatment
with aflibercept), treatment regimens, and treatment outcomes. The correlation analyses
that I performed were run with the NAMD patient data from all three geographically
disperse retinal practices. In the NAMD populations evaluated from the three retinal
practices, there was little correlation between the selected health characteristics as
compared to treatment regimens or to treatment outcomes; however, there were
significant associations noted between treatment regimens and treatment outcomes. I will
use the remainder of Chapter 5 to elaborate the specifics of these findings and provide
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insight into how this research applies not only to prior reviewed literature but also to
what impact this study research could have on future research.
This study was limited by the inaccessibility to the variables of race/ethnicity, iris
color, and genotype in the EMR of the three retinal practices. As such, these three
variables were not a part of the final comparisons. If these variables had been available,
there would have been the opportunity for additional understanding of the health
characteristics of the NAMD population used in this study. Additionally, this study was
somewhat limited by the number of patients originally planned to be captured versus the
amount of data available in the EMR. Although it was the case that data from 199
instead of 252 patients were included, the statistical findings were still robust as I will
further discuss in this chapter.
As for this study’s implications for positive social change, this type of study that
can be performed on existing electronic data could lead to a better understanding of when
and how medications are used. Studies could be performed on a single practice basis or
on larger populations (e.g., city, state, country). Fostering use of EMR data for gaining
an understanding of patient demographics and health characteristics could impact the use
of treatment regimens and lead to better treatment outcomes.
Interpretation of Findings
Results Pertaining to Prior Literature
Comparing the findings of this study to the prior literature reviewed for this study
led to a better understanding of how these three geographically disperse retinal practice
populations fit into the overall population of NAMD patients treated with aflibercept. It
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was unfortunate that the race/ethnicity and iris color data were not available in the EMRs
for the retinal practices used, as this might have increased understanding of the
associations between the variables evaluated. Both the overall (60.8%) and the three
specific NAMD populations (CA = 56.8%, KY = 58.4%, and OH = 68.5%) were made
up of greater numbers of females. This skewing towards a greater risk of developing
NAMD for females is supported by the literature (Coleman et al., 2008; NEI, 2014).
Additionally, the mean age in the general population (78.78 ± 8.542) and the three
specific populations (CA = 79.98 ± 9.449, KY = 77.88 ± 8.222, OH = 79.50 ± 8.332) was
similar to that reported in in prior literature (Lim et al., 2012; NEI, 2015b). With regard
to ocular comorbidities, this study supported the findings of prior literature (The
Foundation of the American Academy of Ophthalmology, 2015) with the finding that the
presence of cataract was noted in 174 (87.4%) of the NAMD patients in the study.
The package insert for aflibercept that provides the instructions for administration
of the product states that aflibercept should be given once per month for the first 3
months and then every other month for the remaining 9 months of the year (FDA, 2011).
This translates to a total of approximately 7.5 doses per year. The findings of this study
were quite close to that recommendation with 7.24 ± 1.861 doses given in the overall
population of 199 patients. Change from baseline BCVA and change from baseline OCT
showed promising increase in visual function (-0.0073 ± 0.30373 logMAR) and decrease
in central macular thickness (-43.8750 ± 96.27885), which are how efficacy of aflibercept
treatment is evaluated in the NAMD patient populations (FDA, 2011).
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Generally, the findings of this study show that the population characteristics of
NAMD patients in the three retinal practices were similar to an epidemiologically
appropriate patient population, at least with respect to the variables that could be
collected from the EMR at the practices used. The number of injections patients receive
in these practices is aligned with the aflibercept package insert. The timing of the
injections was also aligned with the information provided in the aflibercept package
insert.
Results Pertaining to Retinal Practices
Research Questions 1–3 pertained to determining whether the three
geographically disperse retinal practices used in this study were comparable to each
other. I evaluated a total of 1,501 NAMD EMRs for patients at the three retinal practices
to capture information on selected health characteristics, treatment regimens, and
treatment outcomes based on treatment with aflibercept. Of this total, 199 patients were
considered qualified for further review based on the criteria noted Chapter 3. For Tables
16 and 17, a plus sign (+) denotes that the mean differences between the retinal practice
combinations noted in the table for a health characteristic showed not statistically
significant differences. A minus sign (-) denotes that statistically significant mean
differences were noted in the health characteristic noted in the table between the retinal
practice combination noted. The testing performed for the selected health characteristic
comparisons between retinal practices was either a one-way ANOVA or a one-way
Welch ANOVA. My determination of the use of the Welch one-way ANOVA was based
on whether the variances were different between the retinal practices being compared on
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the health characteristics. Table 16 reports comparisons for the selected health
characteristics between the three retinal practices.
Table 16
Comparison of Selected Health Characteristics by Physician Group
Physician

Age

Gender

Ocular

Systemic

Days from

BL

BL

Group

Comor-

Comor-

NAMD Diagnosis

VA

OCT

Combina-

bidities

bidities

to First

tions

Aflibercept
Treatment

CA/KY

+

+

+

+

+

-

-

KY/OH

+

+

+

-

-

+

+

CA/OH

+

+

+

+

-

+

+

Note. “+” denotes no statistically significant difference in the mean differences for site pairing.
“-“ denotes statistically significant difference in the mean differences for site pairing.

The practices were alike in the main demographic and health characteristics of
AGE, GENDER, and OCULAR. No statistically significant differences were noted in
these three general health characteristics, and AGE, GENDER, and OCULAR were
aligned with what has been noted epidemiologically for the NAMD patient population
(NEI, 2014, 2015b). Consequently, I determined that the retinal practices were
representative of the general NAMD population in the health characteristics that were
significant to have been reported by an ophthalmologist (e.g., age, gender, and ocular and
systemic comorbidities).

118
There were more inconsistencies between KY and the other two retinal practices
(i.e., CA and OH) regarding selected health characteristics. In this evaluation, baseline
BCVA and baseline OCT findings were especially notable in the mean difference
between CA and KY. Considering that the mean baseline BCVA for the general
population was 0.53 ± 0.39 logMAR, a mean difference between CA and KY of 0.17
logMAR indicates that KY’s patients were significantly more visually impaired at the
beginning of their aflibercept treatment cycles. The same issue holds true for baseline
OCT. Mean baseline OCT for the general population was 333.26 ± 110.795 µm. The
mean difference reported between CA and KY (70.674 µm), again, means that KY’s
patients started at a much more advanced level or central retinal thickness at the initiation
of their aflibercept treatment cycles. The comparison between KY and OH further
supports the notion that KY’s retinal practice may have been somewhat different with
regard to the health characteristics than either CA or OH.
While not as significant, KY did show a disparity on the number of systemic
medical history items and the days from diagnosis to first treatment with aflibercept. The
differences between the three retinal practices that pertain to NAMD specifically may be
due to the difference in sample size between the three practices. KY accounted for
slightly over 50% of the total patients in this research project. A difference in
methodology for capturing BCVA or OCT assessments or in recording information such
as diagnosis date into the EMR may have caused this practice to exhibit notable
differences. Table 17 reports comparisons for treatment regimens and treatment
outcomes.
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Table 17
Comparison of Treatment Regimens and Treatment Outcomes by Physician Group
Physician

Number of

Number of

Best

Optical

Group

Days between

Treatments

Corrected

Coherence

Combinations

Treatments

Visual Acuity

Tomography

CA/KY

-

-

+

+

KY/OH

+

+

+

+

CA/OH

-

-

+

+

Note. “+” denotes no statistically significant difference in the mean differences for site pairing.
“-“ denotes statistically significant difference in the mean differences for site pairing.

Pertaining to treatment regimens, there were significantly notable differences within
the CA practice as compared to the other two retinal practices. CA provided more
aflibercept treatments (8.55 ± 1.956) to each patient than either KY (7.08 ± 1.647) or OH
(6.46 ± 1.634) with CA having significantly fewer days between aflibercept treatments
(45.9056 ± 16.79308) than OH (58.1092 ± 21.49335) or KY (55.8789 ± 20.76874).
These treatment regimen differences between the three retinal practices did not translate
to significant differences in the treatment outcomes. In general, it appears that the three
retinal practices were quite similar to each other and to the general population of patients
treated for NAMD with aflibercept. Although I noted differences in some of the health
characteristics and aflibercept treatment regimens, this did not translate to significant
differences in the treatment outcomes.
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Results Pertaining to Associations
Research Questions 4–6 pertained to whether there were associations between the
selected health characteristics, treatment regimens, or treatment outcomes in the NAMD
populations I analyzed from the three geographically disperse retinal practices in the
United States. In Table 18, findings for associations between health characteristics and
treatment regimens are reported.
Table 18
Significant Spearman’s Correlations for Selected Health Characteristics, Treatment
Regimens, and Treatment Outcomes
Comparison

Spearman Correlation Coefficient

p-value

AGE + NUMTRT

rs (199) = 0.151

0.033

DIAGTRT + NUMTRT

rs (199) = - 0.200

0.005

DIAGTRT + NUMDAY

rs (199) = - 0.220

0.002

BLVA + BCVA

rs (199) = - 0.308

< 0.001

BLVA + OCT

rs (199) = - 0.193

0.006

BLOCT + OCT

rs (199) = - 0.721

< 0.001

BLOCT + NUMDAY

rs (199) = -0.141

0.047

NUMDAY + OCT

rs (199) = 0.197

0.005

NUMTRT + OCT

rs (199) = - 0.191

0.007

The first of the comparisons in Table 18 indicated that a positive correlation
existed between age at the time of first aflibercept treatment and number of aflibercept
treatments given meaning that as the age at first treatment with aflibercept increased as
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did the number of treatments given. Although this is a statistically significant correlation,
it is not intuitively reasonable. This would seem to mean that the older the patient was
when they were first started aflibercept treatment, the more likely they were to receive
more treatments. This is an interesting correlation, if it were to hold true in future
research, as it may indicate that physicians treat more aggressively with older patients.
There was a negative correlation between both the time from NAMD diagnosis to
first aflibercept treatment as compared to the number of aflibercept treatments given and
the number of days between aflibercept treatments. This indicated that the longer the
time period was between when the subject was diagnosed with NAMD and when they
first received aflibercept treatment, the more likely they were to receive fewer treatments
with aflibercept in a shorter period of time. While neither of these correlations was
strongly negative (-0.200 and -0.220, respectively), the correlation is highly statistically
significant (p = 0.005 and p = 0.002, respectively). This finding indicated that the three
retinal specialists used for this study were seemingly not as aggressive in their treatment
of NAMD patients with more advanced disease.
There was also a negative correlation between baseline BCVA and change from
baseline BCVA, baseline BCVA and change from baseline in OCT, and baseline OCT
and change from baseline OCT. As baseline BCVA increased, change from baseline
BCVA and change from baseline OCT both decreased. As baseline OCT increased,
change from baseline OCT decreased. Decreases in both change from BCVA and in
change from baseline OCT were considered an improvement. The meaning of this was
that with worse initial VA, there was a greater possibility for improvement in both BCVA
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and in OCT findings. As well, increased initial central retinal thickness as seen on OCT
was more likely to improve. The correlations between baseline BCVA and change from
baseline BCVA and change from baseline OCT were not strongly negative (-0.308 and 0.193, respectively) but were highly statistically significant (p < 0.001 and p = 0.006,
respectively). The correlation between baseline OCT and change from baseline OCT was
strongly negative (-0.721) and highly statistically significant (p < 0.001). This indicated
that although a patient may start from a significantly negative assessment in terms of
BLVA and BLOCT findings, there was a correlation with this negative initial assessment
and a greater improvement with aflibercept treatment in these three retinal practices.
Finally, there was a positive correlation between the number of days between
treatments and both baseline OCT and change from baseline in OCT. As the number of
days between treatments increased the baseline OCT was seen to be increased (worse)
and the change from baseline OCT increased (worse). There was a negative correlation
between and the number of treatments given and change from baseline in OCT. As the
number of treatments increased, the change from baseline OCT decreased (better).
When evaluating these results in terms of the burden of treatment theoretical
framework, it is clear that the burden of aflibercept treatment is onerous both on a
financial and a personal basis. Having to receive over seven intravitreal injections over
the course of a year takes not only a great deal of time but also financial and personal
resources as well. However, it can be posited that by receiving these injections, the
appropriate patient population can benefit from the treatment. More treatments may
mean greater time and money, but it may also mean a greater chance to regain some
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visual function. Gaining visual function could lessen the burden of blindness due NAMD
to the benefit of the patient, the healthcare system, and the community.
Limitations of the Study
One of the main limitations of the study with respect to what was originally
planned was that race/ethnicity, iris color, and NAMD genotype were not available in the
EMRs of the retinal practices. This limited the study to examination of age and gender as
the main demographic characteristics that were evaluated. Although this was a significant
limitation, the remainder of the data collected was quite robust and provided an ample
view of how aflibercept treatments are performed and what the outcomes of the
treatments were. A secondary limitation was that the number of cases that could be
culled from the EMR data at the three retinal practices was somewhat lower than
anticipated and was not evenly dispersed between the three practices. Nonetheless, the
power to detect a Type 1 error at an a = 0.05 was maintained at 90% with the 199
patients included in the project.
Recommendations
Since this study supported prior literature and clinical research findings pertaining
to the population, health characteristics, treatment regimens, and treatment outcomes, it is
imperative for this information to be shared and expanded upon in different therapeutic
areas. Use of EMR has been shown to be an effective means of gathering and analyzing
available data to evaluate important medical conditions and treatments. Expanding the
use of EMR in the manner employed in this study is not difficult and not particularly time
consuming. EMR is an untapped resource that could and should be used in
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postmarketing efforts, in clinical research, and public health programs. Additional
studies of interest would be to evaluate other retinal conditions (e.g., diabetic macular
edema, retinal vein occlusion, retinitis pigmentosa) and other treatments to determine
whether the outcomes from different diseases can be followed by using EMR. Further,
looking at the same type of NAMD population as pertains to other treatments would be
elucidating and would not cost a great deal in terms of financial or personal investment.
Finally, the information gleaned from this study could be used to develop public health
initiatives that would target specific populations for early testing, watchful waiting,
prophylactic care with vitamin supplements, and early treatment leading to better
treatment outcomes.
Implications
The major implication of this study is that the clinical research performed in
support of marketing aflibercept as an effective treatment for NAMD has been reinforced
by general use of the product in NAMD patients in the three retinal geographically
disperse practices used. Results of this study will be provided to the three retinal
practices, allowing the retinal specialist at the identified practices to gain more insight
into their NAMD patient population. It is apparent from analysis of the data, NAMD
patients from these three retinal practices did benefit from aflibercept treatment when the
approved dosing regimen was used. As well, the correlation that was seen that increasing
the number of aflibercept treatments and decreasing the number of days between
aflibercept treatments could provide the clinical justification needed to provide additional
treatments when clinically indicated. With NAMD treatment being a significant portion
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of the public financial burden in the form of Medicare payouts (Silver, 2014), this study
may help alleviate some of the uncertainty associated with trying to determine the most
appropriate regimen (i.e., number and timing of aflibercept treatments) for a patient.
Although the financial burden is still onerous, it is justified when treatments are used on
appropriate patient populations
Regarding social change, research that can be performed on existing electronic
data could lead to a better understanding of when and how treatments are used. Fostering
use of EMR data for gaining an understanding of patient demographics and health
characteristics could impact treatment regimens and lead to better treatment outcomes.
Evidence-based and data driven treatment of patients would seem to be an optimal
method of practicing medicine, which drives improvements in the health of the
population. Having access to data collected in EMR, it would behoove a physician to use
the information to the best of his or her ability and to the benefit of his or her patients.
Changing to an electronic format of capturing health information should be a boon to the
medical industry (i.e., both medical practice and public health) for the potential to be
used effectively and efficiently to find, educate, and treat patients. One final implication
for the use of EMR to understand populations and treatments is to share appropriate
information on a patient or summary basis with public health authorities. Again, basing
public health initiatives, programs, budgets, and outcomes on evidence found in EMR
data could lead to better public understanding of disease and treatment.
This study will be shared with each of the practices involved for the retina
specialists to gain a better understanding of their own practice and what can be
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accomplished by mining the data they already have. It is intended that the methods used
to capture and analyze the data for this project will be shared and appropriate personnel
taught how best to find, organize, and analyze the available data. The aim for such
sharing of information is to teach others in medicine and public health how to use data
already available.
Conclusion
Generally, the findings of this study showed that the population characteristics of
NAMD patients evaluated from three retinal practices were similar to an
epidemiologically appropriate patient population (NEI, 2014, 2015a), at least with respect
to the selected health characteristic variables that could be collected from the EMR (e.g.,
age, gender, and ocular and systemic comorbidities). Additionally, treatment regimens
used by these three retinal practices were aligned with the information provided in the
aflibercept package insert. Based on the treatment outcomes of increase in visual
function (BCVA) and decrease in central macular thickness (OCT), the indication is that
aflibercept treatment was effective in the population culled from the three retinal
practices. Finally, the findings are supported by prior literature and indicate that the
foundation laid by aflibercept clinical research performed in support of the approval to
market aflibercept as an effective product for the NAMD patient population was used for
the benefit of the NAMD patients in the three geographically disperse retinal practices.
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